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Introduction
JAMES L. RITCHIE, MD, FACC, JAMES S. FORRESTER, MD, FACC,
ROBERT H. JONES, MD, FACC
Until recently, the primary distinguishing characteristic of
health care in the post-World War II era has been the
explosive introduction of new medical therapies. Today that
characteristic is giving way to a marked emphasis on refining
medical care to optimize its value for individual patients. This
newly prominent task is one that demands processing of large
amounts of diverse information—all of which is aimed at
considering clinical characteristics of an individual patient,
appropriately sequencing decisions and providing services that
yield the greatest value (1). Practitioners can accomplish this
only if they continually update their own medical knowledge
and consistently place newly acquired knowledge in context
with existing information to produce a beneficial impact on
clinical practice.
Knowledge of basic principles of disease processes and their
clinical management—largely provided in medical textbooks
and review articles—is essential, but not by itself sufficient, to
optimize individual care of patients. Another element, increas-
ingly recognized as also essential for optimizing individual
care, is the medical guideline. Guidelines are gaining such
recognition because they uniquely provide a coherently se-
quenced set of recommendations that tightly links specific
information sources with specific information uses (2).
The growing interest in medical guidelines has outpaced the
standardization of terminology used to characterize their di-
versity. The words “guide” and “line” were first joined to refer
to a physical object, such as a rope that marked the optimal
course along a treacherous path. They can be viewed as maps
of common paths taken, derived from synthesis of past expe-
rience, with annotations that list advantages and disadvantages
of reasonable alternatives. Guidelines will of course vary
widely from one to another in their characteristics, just as
characteristics of maps needed by a long-distance trucking
company will differ markedly from those needed by hikers on
mountain trails. In other words, the formatting of both maps
and guidelines must respond to intended use. Terminology
used in this document to refer to some of the most common
guideline formats related to cardiovascular care is presented in
Table 1.
Medical guidelines typically address either of two primary
concerns: 1) the structure of health care—emphasizing appro-
priate facilities, equipment and personnel for delivery of care
for specific disorders; and 2) specific clinical circumstances—
emphasizing the process of making appropriate decisions and
properly rendering needed services.
The 28th Bethesda Conference explored the unifying prin-
ciples of both of these broad concerns—principles that can aid
generalization of medical information into a guideline struc-
ture that is most likely to add quality to health care delivery.
A medical guideline is constructed by completing a task that
may at first seem simple, but is in fact deceptively difficult. That
task, in essence, is to formulate coherent statements of accept-
able responses to common clinical situations. But those re-
sponses in most cases have been internalized by experienced
providers to such an extent that they have become intuitive.
These providers, when confronted with a familiar clinical
scenario, have little difficulty pursuing a reasonable care plan
that is derived from a professional lifetime of internalizing and
structuring a large amount of diverse information. Such plans,
often referred to as paradigms or common practices, have
formed naturally as accumulating experience combines with
logic. That means even highly articulate practitioners can
articulate these intuitively understood structures only with a
reorientation and refocusing of thought.
The largely intuitive application of information in providing
clinical care is analogous to the way information is used to
drive a car. Both tasks require continuous processing to
separate a large amount of irrelevant information (that which
describes the general environment and decision alternatives)
from the relatively small amount of immediately relevant
information (those core elements that are perceived as having
an immediate impact on benefit and risk). Information in the
domain considered most urgent drives the cognition that
directs response to the current specific situation. When behind
the wheel, for example, a speeding driver who has been paying
attention to road signs in order to identify an urgently needed
rest stop will involuntarily and instantaneously cease this
activity and slow his vehicle on spotting a police patrol car. A
similar process, demonstrating a similarly tight linkage be-
tween information need and information source, forms the
core content of a guideline recommendation—and is similarly
easy to visualize but difficult to express.
The core task of the guideline development process is to use
knowledge derived from specific information sources to con-
struct a coherent set of generalizations that serve information
needs in specific health care delivery situations (Fig. 1).
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Common sources of specific information useful in formulating
guidelines include clinical studies, patient care experiences,
general medical knowledge, clinical databases and results of
using previously adopted related guidelines (Fig. 1).
Guideline development and use require precise character-
ization of information under three interrelated descriptors of
content: care process, disease severity and time. The last two of
these domains are familiar to the clinician: The time relation-
ship of medical information may be described in real time or by
event occurrence, such as defining a sequence of care before or
after cardiac catheterization. Disease severity, on the other
hand, is usually described by prognostic markers, for both the
primary and comorbid disease.
Medical guidelines that address care delivery introduce an
additional domain of information that relates to structure
and/or process in health care delivery:
1. Structure is defined to include the qualification of per-
sonnel and types of facilities needed to support care delivery
for specific disorders. Examples of guidelines that are primarily
concerned with descriptions of the structure of care delivery
include those that address credentialing of providers, the need
for referral to a more comprehensive care environment and
the assessment and application of medical technology. Typi-
cally, such guidelines implicitly assume the process of care
delivery to be optimal.
2. Guidelines directed primarily to the process of health
care delivery commonly address care decisions (doing the right
thing) and optimal delivery of those services (doing the thing
right), while implicitly assuming the proper structure to be in
place.
Three of the five task force reports presented at the 28th
Bethesda Conference address structure; two relate directly to
process. The reports address issues that apply directly to the
development and implementation of clinical practice guide-
lines, as well as guidelines for credentialing practitioners,
specialty referral and regulation of medical technology.
This Bethesda Conference explored and defined contem-
porary principles for formulating and using medical guidelines
that share the common objective of enhancing the quality of
cardiovascular care. To achieve this aim, broad input from
diverse interested parties was sought. Among these were
organizations representing managed-care plans; private
groups, such as the Institute of Medicine; professional societies
representing both generalists and specialists; coalitions of
Table 1. Definition of Guidelines
Term Definition Example
Guideline A related set of generalizations derived from past experience arranged
in a coherent structure to facilitate appropriate responses to
specific situations
Trail map
Health care guideline A guideline related to any aspect of medicine, including healthcare
process, policy, regulation, financing, administration, education and
clinical practice
Guideline for technology assessment
Clinical practice guideline A guideline developed to aid practitioner and patient pursuit of the
most appropriate healthcare responses to specific clinical
circumstances
AHCPR guideline for diagnosis and management of
unstable angina; ACC/AHA guideline for
management of the patient with acute myocardial
infarction
Care plan A clinical practice guideline detailing the usual sequence of decisions
and nature and duration of services for a defined episode of care
Care plan for coronary artery bypass graft surgery
Care module Focused descriptions of care delivery for conditions that often occur
as a component need of many care plans for different primary
illnesses and for which specific recommendations are influenced
little by the character of the primary illness
Care module for management of acute atrial fibrillation
in patients admitted to the hospital
Critical pathway The core set of decisions and services described in an appropriate
sequence and schedule most likely to effect an efficient, coordinated
program of treatment
Description of the critical features of the care
experience essential to most efficiently manage the
usual patient undergoing coronary artery bypass
graft surgery
ACC 5 American College of Cardiology; AHA 5 American Heart Association; AHCPR 5 Agency for Health Care Policy and Research.
Figure 1. Clinical practice guidelines as unify-
ing generalizations of information.
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patients; and many government organizations, including the
Agency for Health Care Policy and Research; the National
Heart, Lung and Blood Institute; the Department of Veterans
Affairs; the Library of Medicine; the Health Care Financing
Administration; and the Food and Drug Administration.
The task force reports that follow, therefore, reflect not
only the initial efforts of appointed writing groups, but also the
broader input gained from the entire conference. We hope that
these discussions and recommendations, as guided by the
American College of Cardiology and the American Heart
Association, will provide a broad framework for the ongoing
development and use of guidelines by the cardiovascular
community.
References
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TASK FORCES
Task Force 1: Clinical Practice Guideline Development, Dissemination
and Computerization
ROBERT H. JONES, MD, FACC, CO-CHAIR, JAMES L. RITCHIE, MD, FACC, CO-CHAIR,
BARBARA B. FLEMING, MD, PHD, KARL E. HAMMERMEISTER, MD, FACC,
LUCIAN L. LEAPE, MD
Character and Uses of Clinical
Practice Guidelines
Clinical practice guidelines are developed primarily to serve
patient care needs. Other uses are secondary in importance
(1). Guideline recommendations focus on the usual manage-
ment of the average patient with a specific disorder and are not
expected to be applicable to every patient because of the
complexity of human biology and the fragmented nature of
medical knowledge. Guidelines are used most effectively when
the linkage to the underlying evidence is described, so that any
necessary deviations from usual practice can be placed in
proper context. Guidelines may serve to reduce practice vari-
ation, enhance care continuity, and improve interprovider
communication during the care process, especially when deci-
sions are made and services rendered by multiple providers
and in different care settings (2,3). Guideline statements of
common medical practice also provide starting points for
patients and providers to discuss care options most consistent
with individual patient needs and preferences (4,5).
Medical guidelines highlight critical clinical information
needed at the major decision points in disease management
and therefore define the core content of the medical record
(6). Explicit, standardized definitions characteristic of good
guidelines, encourage consistent entry of this information into
the medical record and thereby facilitate meaningful compar-
ison of quality and costs of care among institutions and practitio-
ners. The burden of care documentation can also be diminished
by incorporating templates of commonly used order sets or notes
in a form that can be easily individualized for each patient.
The quality of a guideline is measured in terms of clarity,
clinical applicability, and flexibility both for the individual
guideline recommendations and for their coherent integration
into a functional form (7). These attributes and the reliability
and reproducibility of a guideline are assessed objectively by
quantitating their impact on measured outcomes of care.
Results of guideline assessment provide useful information to
aid revision and continuous improvement of the instrument (8).
Clinical practice guidelines may be created for a variety of
cardiovascular conditions and procedures. The final form of a
specific guideline will be determined by the projected scope of
the topic and its intended audience and uses. General princi-
ples basic to the guideline development process can be defined
that are readily adaptable to the needs of different guideline
development situations. This document offers such a guideline
for the development of clinical practice guidelines that appears
well suited to the needs of the American College of Cardiology
(ACC) and the American Heart Association (AHA). The
principles described can readily be adapted by other groups for
other specific uses.
A comprehensive process beginning with consideration of
development of new clinical practice guidelines for common
cardiac conditions and ending with a process for continuously
improving these guidelines based upon results of their imple-
mentation can be divided into eight discrete phases defined by
the general sequence of work objectives. These phases are
described separately to facilitate communication of specific
recommendations most appropriate to the principal work
objective of each phase, with the realization that the actual
process will represent a continuity of phases that overlap in
time and contribution by different individuals.
Guideline for Development of Clinical
Practice Guidelines
Phase 1. Administrative Oversight
Task 1. Responsible individuals from organizations con-
templating guideline development identify the specific goals of
the guideline to assure that expectations are consistent with the
basic mission and resources of the organization.
Task 2. Knowledgeable experts prioritize possible guide-
line topics based upon the number of patients affected, the
seriousness of the condition, and the magnitude of change in
health outcomes likely to result from adherence to the pro-
posed practice guideline.
Task 3. A literature review is conducted to better define
the scope of the topic, anticipated development costs, and
timeline for completion of each phase of work.
Comment on phase 1 work. Underestimating the scope of
the task is a common problem in guideline development. The
production costs should be matched with the long-term benefit
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expected by the developing organization. Topics should be
selected to fit needs, and redundant guideline development
efforts must be avoided. To avoid duplication, the ACC and
AHA should provide all interested parties with a list of
planned and ongoing cardiovascular guidelines.
The cost of development of a clinical guideline is deter-
mined primarily by the extensiveness of literature review, the
quality of evidence synthesis, travel, and publication costs.
Existing guidelines differ greatly in the number of citations
supporting the recommendations and on the processes used
for retrieval, review, and evaluation of those citations. Al-
though extensive literature review and distillation should yield
the best guideline, the most cost-effective methods for doing so
have not been determined. Guidelines developed by the
Agency for Health Care Policy and Research (AHCPR) have
usually cost about $1,000,000, and much of this cost was
incurred by the extensive literature review conducted. Analysis
of literature review for three early guidelines developed by this
group suggest that only 1%–5% of the 6,000 to 18,000 refer-
ences reviewed were ultimately cited in the final document,
suggesting that this approach could be shortened (Cahn M,
Jones RH. Personal communication, 1996). Many professional
societies have developed guidelines using member volunteers
supported by a small professional staff at a cost ranging from
$10,000 to $200,000. These less expensive approaches stream-
line the literature review by combining references cited by
recent high quality review articles on the clinical topic, to
which more recent articles are added by focused literature
reviews and expert panel knowledge of the literature.
Phase 2. Select Expert Panel
Task 1. An expert panel balanced for diversity of experi-
ence and expertise, must be motivated and possess group
interaction skills. They must also commit to the timeline for
work completion.
Task 2. The expert panel should be convened by e-mail,
teleconferencing, or videoconferencing to discuss the initial
guideline development plan and suggest further work to be
completed before the first face to face meeting.
Task 3. The expert panel should revise or accept the
topical outline and begin the design of a patient flow algorithm
and consider the step-by-step guideline recommendation link-
ages to identify areas of controversy as a basis for focused
literature review.
Comment on phase 2 work. An ideal clinical practice
guideline development process joins information distilled from
the scientific literature with knowledge of expert practitioners
to form the set of recommendations that are specific, precise,
coherent, and comprehensive. The paucity of hard data eval-
uating efficacy of treatments for most conditions and the
complexity of placing the evidence that does exist in proper
clinical context, argues for evidence to be evaluated by experts
who know both the strengths and the weaknesses of clinical
study methodology. Conditions or procedures for which little
scientific evidence of efficacy exists are often also those in
greatest need of practice guidelines, which must be derived
primarily from expert opinion.
An expert panel should include practitioners with intimate
familiarity with the clinical realities of patient care and exper-
tise in evaluating the quality of the scientific evidence. Cardio-
vascular specialists bring knowledge essential to contextualiz-
ing information about cardiac conditions. Members of other
related specialties who care for cardiac patients bring a broad
clinical perspective. Primary care physicians, such as internists,
pediatricians, and family practitioners, contribute unique in-
sights.
Phase 3. Literature Search and Evidence
Gathering Review
Task 1. A computerized literature search constrained by
publication time and language should focus on key words most
likely to yield articles related to guideline topics of greatest
controversy.
Task 2. All relevant abstracts related to each topic should
be matched to the guideline outline and coded by an index of
study design (A 5 randomized trial or meta-analysis; B 5 well
controlled clinical study; C 5 other clinical study).
Task 3. Results from relevant articles should be compiled
into evidence tables that include the best evidence available for
each topic. Class C evidence should be reviewed for those
topics without class A or B evidence.
Task 4. Evidence should be reflected by precise wording of
each recommendation to emphasize the importance of each
recommended action, and an associated strength of evidence
code should correspond to the highest level of evidence
available.
Comment on phase 3 work. The completeness of the
search is determined primarily by the number of key words
used, the publication date, and publication language. The
cost-effectiveness of the search product will be enhanced by a
detailed outline of the full guideline to organize key words and
to use general knowledge of the literature to identify times and
languages most likely to yield major scientific contributions.
For example, a literature search on a procedure might focus on
only that time when the procedure became clinically mature.
Conversely, some of the most important natural history key
words might also be searched during an early time period
before newer treatment modalities altered the natural history
of a disease. Commercial software programs facilitate abstract
review and organization.
The full scientific studies must be reviewed by one or more
individuals to evaluate the strength of study methodology and
clinical relevance. Published meta-analysis of good quality can
be used as published or updated by more recent trials. Ran-
domized trials not suitable for meta-analysis and good clinical
studies are often best synthesized using an evidence table.
These tables are designed to compare study results by properly
weighing differences in study methodology and the manner of
reporting results. The major difficulty in using nonrandomized
data is that physician bias in selecting alternative treatments
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may be difficult to separate from intrinsic therapeutic efficacy.
The major concern about the use of conclusions from random-
ized trials relates to the generalizability of results to a broader
population than that included in the trial. A number of
quantitative schemes have been advocated to grade “evidence”
in the scientific literature, but none has evolved as standard.
However, all evidence based guidelines should explicitly de-
scribe the methodology used.
All schemes used to relate evidence to individual guideline
recommendations should convey the magnitude of difference
of the alternate care strategy recommended and the certainty
of this difference. The strength of a recommendation therefore
relates most to the benefit or harm expected if a recommen-
dation is followed or ignored. The strength of a recommenda-
tion can be conveyed by precise and consistent use of language,
especially verbs such as “must,” “should,” or “may be consid-
ered.” Alternatively, a predefined numeric code, such as that
used by ACC/AHA (Class I, II, III*) may rank the strength of
each recommendation. The certainty of a recommendation
relates to the strength of the scientific literature or expert
opinion or both.
It seems intuitive that strong recommendations would be
those with a large amount of evidence. However, some of the
most obvious components of care delivery that are uniformly
considered necessary, such as putting pressure on a bleeding
site or performing a history and physical examination, have not
been and are unlikely to be subjected to rigorous scientific
testing. Therefore, a strategy that separates these two compo-
nents of recommendation validity may appear contradictory on
the surface, with recommendations using the words “should
always” also having weak strength of evidence. Conversely,
some recommendations may clearly state there is no difference
between two therapeutic alternatives, with a strong strength of
evidence grade, if a number of randomized trials support this
conclusion.
Phase 4. Consensus Process
Task 1. Guideline authors must converge upon specific
positive or negative recommendations by consensus or by a
confidential vote using an explicit process that ensures an equal
voice for each participant when controversy exists.
Comment on phase 4 work. Many recommendations can be
made with little discussion and unanimous consent. However,
panel consensus on controversial recommendations should be
addressed by a structured process using confidential voting to
eliminate pressure to conform and to reduce the dominance of
forceful personalities or authority figures. This process also
serves to document the extent to which consensus existed after
the issues were discussed. Users of guidelines often benefit as
much from knowing when experts disagree as knowing when
they agree.
The most objective approach to quantifying expert opinion
has been the RAND appropriateness scale (9, 10). This score
has been used primarily to quantitate expert opinion about
appropriateness and necessity of alternative treatment strate-
gies (where a 9 indicates a clear positive action, 1 indicates a
clear negative action, and 5 indicates an equivocal situation).
This scoring system provides an approach to separate magni-
tude of benefit from certainty. If every panel member grades a
decision as 5 making a mean of 5, the group seems certain that
there is no difference between two therapies. However, a mean
of 5 could also result from half the panel assigning a 9 score
and the other half a 1 score where the statement of no clear
benefit would be made with much less certainty.
“Negative” recommendations—a judgment that a service is
not indicated—are as valuable as positive recommendations.
When it is possible to make unambiguous statements, they
have great value. When it is not, then the lack of consensus or
agreement that “we don’t know” is important information for
practitioners.
The process for developing guidelines, including the meth-
ods for analyzing the evidence, selecting panel members, and
distilling group judgments into specific recommendations,
should be monitored and approved by the appropriate author-
ities of the convening body. The credibility of professional
society guidelines is enhanced by the objectivity of a thorough
outside review. The process of incorporating results of this
review into final appoval by the panel should be described.
Phase 5. Computerize Guideline Documents in
Format for Clinical Use
Task 1. Authors should construct a computerized form of
the core guideline that links sequenced recommendations with
related branching information trees constructed in hierarchical
levels.
Task 2. A computer program organized by the core guide-
line algorithm should be prepared to capture information
needed to create clinical notes, orders, and care records for
common phases in the care delivery process that use prefor-
matted information templates to simplify data entry.
Task 3. A computer program should be developed to link
information from important variable fields in clinical notes into
a structured database suitable for assessing adherence to
guideline recommendations and monitoring performance mea-
surements.
Comment on phase 5 work. Computerization promises to
enhance the usefulness of clinical practice by facilitating three
aspects of use. The most basic reason to convert text into
electronic form is the ease of storage and transmission from
physical compression of the document. However, a more
meaningful organization of guideline documents results when
information is arranged in hierarchically related information
trees. This form of information storage permits users to search
*Class I 5 conditions for which there is evidence and/or general agreement
that a given procedure or treatment is useful and effective. Class II 5 conditions
for which there is conflicting evidence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment. Class III 5 conditions for which
there is evidence and/or general agreement that the procedure/treatment is not
useful/effective, and in some cases may be harmful.
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on items of interest and retrieve topically oriented information
at any level of detail appropriate to immediate needs. For
example, information on aspirin use in patients with acute
ischemic heart disease syndromes might be organized around
specific recommendations so that users might branch into
specific details of evidence cited related to dosage or route of
administration. Moreover, detailed expert opinion about the
relative risk and benefits of aspirin in patients who also have a
comorbid disorder such as peptic ulcer disease might be
explored in a level of detail that would not be reasonable in
printed documents. However, the most compelling reason to
computerize guidelines is to fully integrate guideline recom-
mendations with the care process in real time by prompting
entry of information on well defined clinical variables at the
point of care. This structure will simultaneously generate notes
and orders while prospectively recording information for later
analysis by quality of care instruments. The current state of
development of computerization of guidelines demonstrates
that all of these potential uses are feasible.
Guideline computerization requires delineation of a core
algorithm describing the usual order of patient management.
Constructing this algorithm during the guideline development
process is facilitated by identification of a coherent linkage of
guideline recommendations. Clinical algorithms are guides to
the stepwise evaluation and management strategies that in-
clude 1) ordered sequences of steps of care, 2) required
observations to be made, 3) decisions to be considered, and 4)
actions to be taken. Clinical practice guidelines in an algorith-
mic format have been shown to be more effective in achieving
guideline compliance than those in the usual narrative format
(11–16). Multiple interlocking algorithms related to discrete
phases of care are often more useful than a single extensive
algorithm. Figure 1 illustrates a standard set of symbols for
graphically displaying the ordered sequence of care adopted by
the Society for Medical Clinical Decision Making (17). An
algorithm requiring discrete yes/no decisions for specific pa-
tient circumstance may be difficult to develop but is basic for
successful linkage of the clinical practice guideline to a medical
information database (18).
Phase 6. Test and Revise Guideline
Task 1. The expert panel or their representatives should
evaluate the computerized form of the guideline during actual
patient care to assess the clarity and reasonableness of each
recommendation applied during actual clinical care.
Task 2. Deficiencies of the guideline identified by initial
limited use should serve as the basis of final revision of the
guideline in a final printed and computerized version.
Comment on phase 6 work. Although the graphical, algo-
rithmic format simplifies content and aids comprehension of
guideline principles, many recommendations that appear rea-
sonable when read prove unworkable in clinical practice. For
guidelines to become a regular part of clinical decision making,
Figure 1. Standardized symbols for displaying guide-
lines in graphic algorithmic format. The oval, which
appears at the beginning of each flow diagram, defines
the population of patients under consideration. The
hexagons are dichotomous decision nodes, which have
one arrow (group of patients) entering and two leaving.
An arrow going to the right from the decision node
indicates the group of patients defined by a yes or
positive response to the question posed, whereas an
arrow going down indicates patients defined by a no or
negative response. The rectangle summarizes a recom-
mended process or set of diagnostic and/or therapeutic
processes of care for the designated group of patients.
Each oval, hexagon, and rectangle is numbered sequen-
tially from top down and left to right. The small circle,
which always contains a number, indicates that the
sequence of care skips to the next hexagon or rectangle
with that number. The asterisk indicates that a set of
detailed criteria (for decision nodes) or processes of care
are contained in an appended table numbered the same
as the hexagon or rectangle. Reprinted, with permission,
from Society for Medical Decision Making Committee
on Standardization of Clinical Algorithms. Med Decis
Making 1992;12:149–54.
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they should be incorporated smoothly into the usual activities
of care delivery and recognize the need for variation of care for
specific patients (19,20). Some of these variations in processes
of care should be reflected in the guideline content to enhance
clinical applicability. Incorporation of the guidelines into an
electronic medical record offers the advantages of storage of
individual patient data which can drive retrieval and display
of a guideline based upon characteristics specific to the illness
of that specific patient (Fig. 2) (21). Figure 2 illustrates the
conceptual model of how an automated medical record might
incorporate practice guidelines as a real-time, point-of-care
clinical decision support tool. Integration of care documenta-
tion with care delivery facilitates extraction of performance
measures.
Phase 7. Disseminate Guideline
Task 1. Disseminate the guideline in full and summarized
printed forms and in appropriate computerized forms.
Task 2. Encourage use of guideline content in a comput-
erized version that facilitates customizing and revising by users
while retaining functionality of databasing and assessment of
frequency of adherence to major guideline recommendations.
Comment on phase 7 work. A printed or computerized
version of a guideline with uniform content is useful in the role
of a medical textbook, but the guideline is more likely to find
direct clinical use if it can be adapted to local practice while
retaining core content (22). A program permitting practitio-
ners to customize a guideline to their own use within an
acceptable boundary of variation might be effective (23).
Phase 8. Revise and Refine Guideline
Task 1. Maintain ongoing annual literature review by
adding new evidence and revising the wording or strength of
evidence grading of corresponding recommendations.
Task 2. Use data from guideline use to define management
strategies based upon risk stratified outcome variables.
Task 3. Develop increasingly explicit guideline paths for
management decisions that are supported with good outcomes.
Comment on phase 8 work. Improvement of the quality of
care is the only justification for implementing clinical practice
guidelines. Clinical data acquired during clinical care directed
by a guideline can be used both to assess the quality of care
delivered and the quality of the guideline used (24).
Overview of General Principles of
Assessment of Quality of Care
Evolution of Quality of Care Assessment
Evaluation of quality has always been an integral part of
good medical practice. Practitioners regularly assess the ap-
propriateness of their decisions and monitor the outcomes of
patients under their care. The thoughtful review of care by
Figure 2. The Veterans Health Administration
conceptual model for using a computerized guide-
line has as its center the patient (point 1) interact-
ing with a care provider (point 2). This interaction
results in measurable healthcare outcomes (point 3)
minus healthcare resources used (point 4). Data
representing the prespecified, minimum informa-
tion content describing the patient-care provider
interaction is input (arrow 5) in encoded format
(continuous or discrete variables), as opposed to
the commonly used free-form, narrative format.
The patient may also enter encoded information
describing his/her illness and preferences for care
(arrow 6). The data input in encoded format are
used in the logic required to retrieve patient specific
practice guidelines and other clinical decision aids
(arrows 9 and 10) for delivery in real-time to the
point-of-care (arrow 11). A by-product of this ap-
proach to documentation of care is a clinically
detailed database that can be used for quality
assessment and improvement, health system man-
agement, and research. The right half of Figure 2
illustrates how this database might be used. The
first step is aggregation across groups of patients
(e.g., defined by medical center) and analysis to
produce risk-adjustment of outcomes and costs
(arrow 12). After review and interpretation by the
peer quality improvement committee (arrow 13),
the data should be sent to the care provider for
comment. Data made available to medical center
and system management (arrow 15) may prompt
communication with care providers (arrow 16).
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individuals or small groups of healthcare providers remains the
cornerstone of quality of care efforts. No integrated approach
for consistent review of quality of care has been universally
accepted. Early quality improvement efforts often used ran-
dom screening of a fraction of medical records to identify
noncompliance with specified targets. This emphasis on the
identification and justification of occasional outliers from
accepted principles of care delivery ignored information de-
scribing usual patterns of care which better reflect quality in
most patient care settings. The opportunity to make good care
even better was lost. Quality assessment programs designed to
identify care deficiencies proved expensive, burdensome and
effective only in identifying low quality care. The punitive
aspect of this approach to quality assessment often prompted
practitioners to concentrate excessively on the way information
was entered into the medical record. Physicians were occasion-
ally tempted to treat the patient’s chart so as not to be judged
as providing deficient quality of care.
Evaluation of quality of care has been redirected more
recently toward the primary goal of providing healthcare
practitioners with information that might be used to improve
the overall quality of care, with a secondary goal of identifying
deficient care. Methodology to accomplish these goals is still
evolving, but initial work has identified a number of attributes
of evaluation programs that enhance quality of care. The best
programs are voluntary and not compulsory, and the incentive
for implementation by practitioners is recognition that the
resulting information is likely to make care more effective and
less costly. Standardized definitions are essential to appropri-
ately characterize important clinical variables, especially those
that relate to the severity of illness at the time of presentation.
Evaluation programs must be applicable to an increasingly
complex set of medical technologies and systems where pa-
tients may be transferred among different practitioners and
different care environments to receive care for a single illness.
The cost of evaluating the quality of healthcare has the
potential to exceed the cost of care actually provided, and
priority must be given to developing evaluation instruments
that are inexpensive and largely invisible to good practitioners.
This implies that, whenever possible, information used to
evaluate quality should be that routinely obtained during
patient care (Fig. 3).
Relationship of Clinical Practice Guidelines to
Quality of Care Assessment
The purpose of both clinical practice guidelines and evalu-
ation instruments is to increase the quality and value of
healthcare (25). Clinical practice guidelines provide definitions
of clinical conditions and outline commonly used care strate-
gies. This organization of information facilitates the develop-
ment of objective instruments to evaluate quality of care.
While the guideline explores the rationale and evidence behind
recommendations for care, the evaluation instruments turn the
guideline recommendations into quantifiable measures of care
actually provided. Evaluation instruments may be structured to
assess compliance with all guideline recommendations under
the assumption that the uniform application of these recom-
Figure 3. A relationship exists between practice
guidelines and performance measures. Perfor-
mance measures consist of three parts: 1) a chart
abstraction data set, 2) logic statements that use the
chart abstraction data set to categorize the status of
a performance measure in a given patient, and 3)
branching data collection so that every data ele-
ment does not have to be collected for every
patient. The chart abstraction data set is derived
directly from the clinical decision criteria (arrow 4).
The performance measure logic is derived from
clinical decision node criteria and the flow diagram
showing the linked, dichotomous, clinical decision
nodes (arrows 2 and 3). The structure for branch-
ing data collection is derived from the flow dia-
gram (arrow 1). The automated medical record/
computerized clinical decision support system may
be derived from the practice guideline in an algo-
rithmic format. The encoded data set (minimum
information content) is derived from the clinical
decision criteria of the guideline (arrow 4) and the
chart abstraction data set of the performance mea-
sure (arrow 8). The logic required for retrieving the
real-time clinical decision aids is derived from both
the chart abstraction data set and logic of the
performance measure (arrows 6 and 7), whereas
the design of the branching data collection can be
derived from the linked clinical decision nodes of
the guideline (arrow 1) and the performance mea-
sure branching data collection (arrow 5).
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mendations will enhance quality of care. However, a more
practical approach emphasizes the major recommendations of
guidelines, especially those well supported by scientific evi-
dence, to identify aspects of care most likely to relate to overall
quality. The use of evaluation instruments provides data from
actual clinical practice that can be used to validate or revise the
guideline recommendations from which these instruments
were devised, thereby providing a framework for continuous
improvement in the organization of information used in pa-
tient care.
Structures, Processes, and Outcomes as Quality of
Care Indicators
Terminology related to instruments used to evaluate quality
of health care is defined in Table 1. Appropriately structured
support systems must be in place to permit delivery of high
quality health care. Indicators of these structures of care
describe the availability of appropriate personnel, resources,
and care environments. The components essential to the
structure of care are often explicitly specified in the clinical
practice guideline. Therefore, the evaluation of process and
outcome indicators of care delivered by the guideline is
undertaken with the assumption that the structure of the care
delivery system is appropriate.
Process indicators include decisions made or services used
in the course of diagnosis and treatment of patients. Process
indicators describe the clinical practice guidelines recom-
mended response to a specific set of clinical circumstances.
These indicators are most useful for evaluating quality when
applied to well defined individual steps of care, but are less
effective indicators of quality for evaluation of complex man-
agement decisions requiring subtle clinical judgment.
The degree of compliance with process indicators measured
by these evaluation instruments is dependent upon the com-
pleteness of the list of exceptions to the indicator which
account for variations in clinical circumstances among patients.
The more extensive the list of exceptions to the indicator, the
more likely that compliance with that indicator will approach
100 percent. However, exhaustive descriptions of possible
exceptions to the process indicators increase the complexity
and cost of evaluation efforts. Therefore, descriptions of
process indicators that include most common clinical excep-
tions will produce a usable instrument. The one exception that
applies to all indicators is patient refusal to consent to the
recommended treatment.
Outcome indicators are measures of the clinical result of
care that has been determined by the structure or process of
healthcare delivery. Improved outcomes usually result from
improved structures and processes of care. The outcomes of
care valued by patients and practitioners include survival,
freedom from disability, reasonableness of cost, and satisfac-
tion with the processes of care.
Simple tabulations of observed outcomes may be used to
compare changes over time in care environments with reason-
ably constant patient populations. However, the use of unad-
justed outcomes to compare quality of care given by different
providers or healthcare systems is usually not appropriate,
since outcomes may also be influenced by patient characteris-
tics unrelated to the quality of care rendered, such as severity
of illness, comorbidity, and age. Therefore, raw outcomes data
must usually be adjusted for patient-based factors which are
beyond the control of the healthcare provider if they are to be
used as comparative indicators of quality. Failure to make
these adjustments may bias providers against involvement with
high-risk patients, who are more likely to have negative
outcomes. When appropriately adjusted, outcome measure-
ments can be compared to standards of quality and become a
valuable tool for quality of care assessment.
Adjustment of outcomes data to control for severity of
illness requires that a consistent set of data be collected and
that valid statistical methods be used to adjust observed
outcomes for baseline differences in populations. Variables of
importance in patients with cardiac disease often include those
relating to general health status, such as age and comorbid
disease, and those specifically related to the severity of the
cardiac disorder, such as coronary anatomy and left ventricular
ejection fraction.
Process and outcome indicators have intrinsic strengths and
weaknesses which must be considered in designing an ideal
system for evaluation of quality of care. Simultaneous atten-
tion to both outcome and process indicators avoids the risk
that providers may emphasize the desired documentation of
process descriptions in the medical chart and decrease the
feeling of responsibility for the ultimate outcome of the
patient. Quality improvement programs must never encourage
providers to improve process indicators at the expense of care
focused on the needs of the patient.
Those who develop clinical practice guidelines are urged to
simultaneously suggest specific outcome and process measures
that can be used to evaluate quality of care for the disorder
Table 1. Definition of Quality of Care Terms
Medical review criteria: Statements of specific patient care processes or
outcomes developed to monitor appropriateness of healthcare
Outcome performance measures: Statistical tools that appropriately adjust
factors which influence observed outcomes but are outside the control of
healthcare providers
Outcome performance measurements: Quantitative statements of outcomes of
care given by individual healthcare providers, groups of healthcare
providers, healthcare institutions, or healthcare systems adjusted by
performance measures for comparison with specified standards of quality to
indicate quality of patient care being evaluated
Process performance rate: The frequency with which a specified process of
care is followed in actual practice
Standards of quality: Quantitative statements of the goal or range expected
for outcome performance measurements or process performance rates
calculated for a specific medical review criterion when applied to care
received by a defined patient population
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addressed by the guideline. These measures will usually derive
from recommendations that may be made with the strongest
evidence. Additionally, the practicality of acquiring valid data
for these assessments must be considered. Outcome measures
are most applicable to groups of providers who treat large
populations of similar patients. Process performance rates
reflecting individual provider compliance with a guideline
recommendation provide an indicator of quality, even for
those who manage only a few patients with a disorder.
Appropriate Uses of Quality Indicators
Quality indicators should be designed to meet the needs of
specific care environments. Resources available for quality
improvement initiatives should be devoted first to those areas
of care which have the greatest potential for improvement.
However, the areas of patient care requiring attention will vary
by the setting and the sophistication of the quality improve-
ment program. For example, the focus of quality improvement
may be specific and well-defined, such as the perception that
aspirin is being underutilized in the care of patients with
unstable angina. Regardless of the complexity or simplicity of
the evaluation program, it is important to state the goals and
purpose of the program at the outset so that appropriate
indicators can be selected. Proper use of these indicators in
continuous quality improvement efforts is likely to greatly
improve the care of patients with cardiac disorders.
Possible Future Uses of Quality Indicators
All medical decisions regarding alternate strategies for
diagnosis and management of patients balance potential risks
and benefits. Excessive attention to only one side of the risk
and benefit equation necessary to optimize a single measure-
ment of performance may detract from overall quality of care.
Therefore, future approaches to assessing the quality of
healthcare are likely to balance values derived from more than
one individual quality indicator. For example, it would be
inappropriate to monitor only the rate of untoward events in
patients evaluated for unstable angina but not admitted to the
hospital without also monitoring the number of patients with
an admission diagnosis of unstable angina that proved incor-
rect. Even a simple, apparently obvious indicator of quality,
such as a low in hospital mortality rate for unstable angina,
cannot be used as an isolated measurement of performance. A
low mortality rate might reflect high quality but also could be
achieved by admitting a high proportion of patients without
coronary disease or by transferring high-risk patients to other
institutions. The use of appropriate combinations of several
performance indicators will generally best grade the overall
quality of care given to such patients.
Conclusions/Recommendations
The processes for developing effective clinical practice
guidelines have been refined in the last decade and reviewed.
It is recommended that ACC/AHA follow these general steps:
1) prioritization of topics; 2) expert panel selection—to include
both content experts and more generalist practitioners; 3)
focused literature review and compilation of meta-analyses and
evidence tables; 4) ranking of evidence; 5) specifying group
processes, including confidential voting; 6) developing algorithms
and computer-based products; 7) pilot testing; 8) development of
performance measures; and 9) dissemination and updating. Ad-
ditionally, it was recommended that the ACC/AHA maintain an
inventory of guidelines planned and underway and share this
information with all other potentially interested parties, with the
aim of promoting cooperation and limiting duplication.
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The ultimate goal of guideline development is to improve care
as manifest either in better patient outcomes or increased
efficiency. Accomplishing either of these goals requires
changes in physician behavior—a challenge that has proven
difficult for several reasons, including the intense demands on
physician time and, in some settings, incentives that encourage
increased resource use. Implementation of guidelines there-
fore requires consideration of issues including:
● How can information be disseminated most effectively?
● If education alone is not sufficient to achieve the goals of
the guidelines, what other strategies can be used?
● What is the impact of practice profiling?
● Can “real-time” interventions such as critical pathways
allow integration of guidelines into routine care with a
minimum of disruption to the physician?
● What are the medicolegal implications of guidelines?
Although there are limited data available on several of
these issues, it is clear that no single implementation
strategy is appropriate or likely to be successful in all
settings. One major reason is that there are a variety of types
of guidelines. Some describe general principles of care,
while others define in great detail an optimal management
plan. Others still describe ambitious targets, such as ideal
lengths of stay or the time within which thrombolytic
therapy should be administered.
The implementation strategies for these guidelines is also
likely to be influenced by who developed them and who will be
using them. For example, guidelines for the appropriateness
of procedures that have been developed by government-
sponsored groups or professional societies are most useful for
their definitions of inappropriate care. These guidelines tend to
have a broad definition of the indications for a test that can be
considered definitely or possibly appropriate. A similarly broad
definition of appropriateness also usually characterizes the
protocols used by payers to “precertify” elective procedures,
because the consequences of classifying a procedure as inap-
propriate is denial of payment, which is sure to generate
tension between the payer and the physician or patient.
In contrast, guidelines used within provider organizations
do not necessarily have such dire consequences if a case does
not meet certain criteria. For example, if a patient does not
meet appropriateness criteria for a cardiac procedure, the next
step may be a conversation between the patient’s physician and
a local medical director. Or, if a patient does not meet the
target length of stay of a critical pathway, the consequence
is not denial of payment for the last few hospital days, but
rather scrutiny of the patient’s clinical and nonclinical issues
by the provider team. In that setting, stricter appropriate-
ness criteria and more ambitious length of stay targets can
be applied.
Regardless of the purpose or source of a guideline, a
constant challenge is how to disseminate its contents, gain the
support of physicians, and provide incentives for physicians to
follow the recommendations. These incentives may include
direct financial rewards or the avoidance of certain negative
consequences, such as citations from quality assurance com-
mittees or identification as a cost outlier by a medical director.
Thus, the goal of the guideline and the incentives created to
encourage adherence greatly influence the method of guide-
line implementation.
Educational Strategies
Traditional efforts to disseminate practice guidelines have
relied upon passive, impersonal methods, such as publication
of the recommendations in medical journals, but the impact of
purely educational strategies is limited at best. Published
information in the medical literature on randomized trials has
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been shown to lead to changes in practice patterns (1), but
implementation has been far from comprehensive for cardio-
vascular interventions that have been clearly shown to be
beneficial in these studies. Well-designed studies in both
primary care and inpatient studies have also shown that simply
exposing physicians to clinical information and recommenda-
tions can achieve only modest changes (2–4). Distribution of
printed materials alone has been shown in several investiga-
tions to be ineffective in reducing use of contraindicated
antibiotics and other inappropriate prescribing patterns (5,6).
More success has been achieved with strategies that bring
educational messages more directly to the attention of prac-
ticing clinicians. One such strategy is face-to-face consultation
on a specific topic, which is often called “academic counterde-
tailing.” The main principles behind this approach are to
● Conduct surveys to determine baseline knowledge, moti-
vation, and barriers to implementing the practice guide-
line.
● Focus efforts on categories of physicians with practice
patterns most at variance with recommendations.
● Establish credibility through a respected organizational
sponsor.
● Provide authoritative, unbiased information and present
both sides of controversial issues.
● Stimulate two-way discussion.
● Use concise graphic educational material.
● Repeat and reinforce a small number of desired behav-
iors.
Several studies, including one large randomized controlled
trial, have shown that this approach can reduce inappropriate
prescribing patterns and blood transfusions (5–7).
Because academic counterdetailing is expensive and must
be targeted narrowly on a few specific issues, an alternative
strategy employed in some organizations is the identification of
physician opinion leaders as change agents. Opinion leaders
are those physicians whose practice patterns—such as the
adoption of a new drug or test—tend to be quickly adopted by
their peers. Methods have been developed to identify physician
opinion leaders through survey tools (8). One large Canadian
trial demonstrated that opinion leaders in community hospitals
were able to increase rates of trials of labor by 46% (as
opposed to routine cesarean section) without adversely affect-
ing maternal or fetal outcomes (9).
Directed Physician Interaction
Although education alone may not be “sufficient” to cause
change in physician behavior, it may still be “necessary” to
build a foundation for other strategies. These other strategies
tend to confront physicians with information and recommen-
dations that are more specific to individual patients and their
own practice patterns. During the last two decades, several
researchers have evaluated interventions, including retrospec-
tive provision of information, profiling of institutions and
individual physicians, and “real-time” measures in which phy-
sicians are provided with recommendations at the moment
when decisions must be made. Available data indicate that the
effectiveness of these interventions varies widely, and, in all
probability, physicians in many health care organizations are
likely to be exposed to combinations of these interventions in
the future.
Retrospective Feedback
Direct feedback of information to physicians can achieve
further improvements, but the magnitude and durability of the
effects of such feedback have been limited. This approach
usually relies upon audits of medical records, and presentation
to physicians of profiles of their past practice as well as those
of peers compared with standards based upon guidelines. Prior
evaluations of such feedback have yielded mixed results (2),
and some data indicate that feedback is more effective for
increasing use of a recommended service than decreasing use of
inappropriate services (10).
In a study based at a teaching hospital, medical residents
improved the efficiency of their test ordering strategy during an
intervention based upon concurrent chart review and discus-
sion, but the impact of this intervention “washed out” after the
intervention was concluded (11). Furthermore, this interven-
tion was not considered sufficiently practical to be imple-
mented as part of routine care at that institution—at least in
the fiscal environment of the late 1970s.
Other data have raised questions about the effectiveness of
“utilization review” as a method of collecting and feeding back
retrospective data. For example, one study examined the
impact of a temporary substitution of “sham” review for half of
the participants in New York City’s fee-for-service health
insurance plan, while the remainder of the enrollees received
care including actual utilization review (11). During an eight
month study period, there was little evidence that actual
utilization review decreased resource use.
In summary, retrospective feedback is most likely to be
successful
● if led by clinical leaders known to the physicians;
● physicians are able to act upon the information;
● physicians received repeated feedback; and
● feedback is coupled with small group discussion.
Practice Profiling
Physician and institutional profiling of clinical outcomes
and length of stay is becoming increasingly common in both the
public and private sector. Perhaps the best known initiative is
the program in New York State in which the Department of
Health has been collecting and disseminating information on
coronary artery bypass graft surgery (CABG) since 1989. After
adjusting for severity of illness, there was a decrease in
mortality from 4.17% in 1989 to 2.45% in 1992 (12). The
causes for this change are controversial, and hypothesized
causes include
1142 EAGLE ET AL. JACC Vol. 29, No. 6
TASK FORCE 2 May 1997:1125–79
● Increased coding of comorbid conditions so that the
predicted risk of surgery for individual surgeons and
medical centers has increased.
● “Out-migration” of sicker patients to other states because
New York State surgeons were reluctant to perform
surgery.
● Discouraging surgery for higher risk patients even if their
outcomes were likely to be better with surgery than
medicine.
However, at least some data suggest that patients may be
seeking care from more experienced surgeons who have lower
complication rates. During the 1989–1992 period, the percent-
age of patients in New York State undergoing CABG by “low
volume” surgeons (50 or fewer operations per year) decreased
by 25%, and the mortality rate for low-volume surgeons fell by
60% (13).
Public initiatives are not limited to data on clinical out-
comes. Other variables that are being collected and dissemi-
nated include length of stay, overall satisfaction with care, and
compliance with quality standards. These quality standards
tend to emphasize “process” variables, such as performance of
cholesterol assays and mammography according to established
guidelines. In addition, provider organizations and payers
collect and analyze even more detailed information on physi-
cian and hospital efficiency and quality.
The rapid increase in use of physician profiling has been
accompanied by several examinations of the limitations of
available methods (14,15), ethical issues (16), and legal issues
(17). For example, many individual physicians do not have a
sufficient volume of patients in any one diagnostic category to
allow meaningful analysis of their outcomes or resource use.
Therefore, these profiling tools are often considered more
appropriate for evaluation of a system of care, rather than any
single physician.
Although controlled data on this subject are sparse, some
research indicates that physician profiling is effective in reduc-
ing resource use. For example, one study found that introduc-
tion of physician-specific length of stay data at one hospital was
followed by increases in the percentage of physicians who met
benchmark goals, and that changes in length of stay were most
pronounced for physicians who initially had the longest lengths
of stay. Furthermore, reductions in lengths of stay occurred
predominantly in patients with an intermediate severity of
illness, and in the diagnoses with the largest economic impact
(18).
In summary, several studies have documented marked
variation in practice patterns between regions of the country
and among individual physicians (19). Despite concerns about
methodological limitations and potential abuses (20), the use
of practice profiling seems likely to grow in both the public and
private sector. The response to these data may be influenced by
the highly variable financial relationships between payers and
physicians (21).
Real-Time Implementation
To achieve greater impact from guidelines than has been
accomplished through education and practice profiling, many
organizations are seeking to integrate guidelines with routine
care using strategies such as decision aids and critical or clinical
pathways (22,23). These “real-time” strategies—which seek to
intervene at the moment when the physician is making key
decisions—recognize the transient impact on practice patterns
of information or recommendations.
Some data indicate that just making physicians aware of
costs can decrease resource use. In one study, physicians at an
academic primary care medical practice were informed of the
charges for outpatient diagnostic tests by computer as these
tests were ordered. During the intervention period, charges for
tests fell 13% compared to a control group of physicians
without any evidence of an increase in adverse outcomes.
However, the impact of this intervention diminished during a
19-week follow-up period after it was discontinued (23).
Adoption of guidelines by physicians may be influenced by
the content of the guideline, the implementation strategy, and
the incentive system. Unfortunately, most studies examining
practice guideline implementation to date have been per-
formed prior to the widespread proliferation of managed care
and capitation as a form of reimbursement for services pro-
vided. In the past, there were no direct financial incentives for
physicians to follow practice guidelines. Since the use of
capitation and physician “report cards” is now becoming more
widespread, it is possible that many previous research findings
regarding the success and failure of practice guidelines may no
longer be relevant.
Although there are few prospective trials of the impact of
implementation of critical pathways or practice guidelines,
available data indicate that these should be evaluated as is true
of any medical intervention. For example, retrospective data at
one institution suggested that a practice guideline would safely
reduce the cost of caring for patients with pulmonary edema
and congestive heart failure (24). However, when the guideline
was implemented and studied prospectively (25), it was found
to increase lengths of stay and probably costs (an effect that
was opposite of what had been predicted based on the retro-
spective study). Other previously published decision aids may
also have clinical effects that are contrary to what would have
been predicted based upon observational studies and hypo-
thetical experiments.
Low-intensity strategies (e.g., education, written feedback)
are of great interest— but unproved effectiveness—as a
method of real-time dissemination of practice guidelines and
prediction rules. On the surface, these strategies are inherently
attractive because they are less intrusive, less confrontational,
more likely to be approved by physician committees, and less
costly. In a study with a time-series design, written information
was concurrently provided to physicians regarding appropri-
ateness of hospital admission and level of care for patients with
acute chest pain (26). The information was provided on
stickers without direct person-to-person interaction. This
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method of providing information was not associated with a
statistically significant change in patient care. Although the
decision aids used to provide the information appeared to be
very promising in retrospective studies, when disseminated
using a low-intensity strategy, there were no improvements in
patient care.
Another study of patients with acute chest pain examined
the use of a decision aid that had been previously found to
result in significant improvements in patient care when the
information was presented to physicians by a research assistant
(27). In a prospective, controlled trial, this information was
used by physicians for only 2.8% of eligible patients. In a
follow-up survey of the six physicians participating in the study,
all of them believed that the predictive instrument did not
provide them with information they did not already have and
all recommended that the predictive instrument no longer be
used for patient care. Therefore, the scientifically validated
decision aid probably resulted in no significant benefit when
disseminated in this manner.
Higher intensity—and more intrusive—guideline dissemi-
nation strategies have proven to be more effective. In a study of
patients hospitalized with chest pain in a health maintenance
organization, education, endorsement of a guideline by opin-
ion leaders, and concurrent feedback using cues by nurses was
used as the implementation strategy (28). This feedback was
delivered verbally via telephone or in person. This approach
was associated with a reduction in total length of stay from
2.51 6 2.1 versus 1.96 6 1.3 days (22% reduction, p 5 0.03).
The reduction in length of stay for this condition exceeded the
reductions in length of stay for several other conditions during
the study period. Moreover, no adverse effect on serious
complications or the hospital readmission rate was detected.
Other studies examined concurrent feedback of informa-
tion by a respected physician as a dissemination strategy
(29,30). Implementation of a guideline in this manner led to a
0.91-day reduction in hospital length of stay (p 5 0.02) and a
total cost savings of $1,397 per patient (direct and indirect
costs summed together) (p 5 0.03) (29). There was no
significant difference in hospital complications, complications
following discharge, readmission rate, and patient satisfaction
when measured 1 month after hospital discharge. The esti-
mated cost savings was almost 15 times the cost of the
intervention. Importantly, when concurrent person-to-person
feedback was withdrawn, practice reverted back to patterns
that had been present prior to the intervention, demonstrating
that person-to-person feedback rather than widespread dis-
semination of the guideline was responsible for the observed
effects. A second study evaluating the timing of transfer of
patients out of the coronary care unit yielded similar findings
(30).
Similar findings on the potential benefit from such direct
interventions were reported by Eagle et al. (31) in a teaching
hospital setting, where guidelines were developed for the
management of patients with chest pain, pulmonary edema,
and syncope. Practice guidelines were disseminated by direct
person-to-person feedback (cardiologist to house staff) and
weekly review of patients. The provision of guidelines by direct
feedback resulted in length of stay reductions of 1.2 days and
increased compliance with the guidelines. There was no differ-
ence in mortality or hospital readmission rates.
In another study involving person-to-person delivery of
information, a research assistant provided physicians with the
probability of acute ischemic heart disease for individual
patients (32). This intervention was associated with a decrease
in patients not having acute ischemia hospitalized in the
coronary care unit of 30%. The percentage of coronary care
unit admissions that were classified as patients without acute
ischemia decreased from 44% to 33%. Therefore, provision of
risk information in this manner was associated with a signifi-
cant change in physician behavior.
Critical Pathways
Critical pathways have been borrowed from industry where
they have been used as management techniques, and recently
emerged as strategies for improving the quality and cost-
effectiveness of medical care (23). These pathways are distinct
from the practice guidelines developed by organizations such
as the Agency for Health Care Policy and Research (AHCPR)
and the American College of Cardiology (ACC) and the
American Heart Association (AHA) in that they tend to be
aimed at the achievement of a few resource use and/or quality
goals. They can potentially represent the translation of the
recommendations from a practice guideline into actual clinical
practice. Unfortunately, there are very few available data
regarding the effect of clinical pathways on patient care.
Furthermore, many of the available studies have serious
methodological limitations (23), but “case studies” suggest that
this strategy has such potential that pathways are being imple-
mented at many if not most institutions.
In one study, a critical pathway was implemented through a
multidisciplinary effort of cardiac surgeons, anesthesiologists,
nurses, case managers, dieticians, and physical therapists (33).
Introduction of the critical pathway was associated with a
reduction in total length of stay (11.1 6 6 days versus 7.7 6 2.3
days, p , 0.0001). The mean hospital cost was reduced by
$1,181 after implementation of the critical pathway (14%
reduction in direct costs per patient, p , 0.0001).There was no
statistically significant difference in postoperative mortality
and hospital readmission rates.
Another critical pathway technique was used to address the
postoperative care provided to children with congenital heart
disease. Implementation of the pathway with attention to key
decision points was associated with significant reductions in
length of hospital stay (34,35). Reductions in lengths of stay
were achieved without compromising mortality, morbidity,
readmission, unscheduled emergency room visits, or a negative
family assessment of care. The critical pathway was associated
with a decrease in length of stay without evidence of compro-
mised patient outcomes.
An important issue in the development of any program
aimed at improving the efficiency and quality of care is whether
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all protocols and pathways must be developed locally, or
whether national groups might be able to supply such guide-
lines. The similarity of the pathways and protocols in place at
many institutions suggests that a national body might be able to
provide the basic structure of a pathway, but the need for local
“buy-in” suggests that the users of these pathways should have
the opportunity to revise and update them.
Another important issue for the implementation of path-
ways or protocols is the need for a readily available approach
for instances in which the patient and/or his or her physician do
not agree with the recommended strategy. An appeals mech-
anism that provides rapid and well-considered responses is
critical for the acceptability of any such program. Ideally, the
discussion in these cases should not focus on whether a
proposed intervention should be “denied,” but rather on which
of the available alternatives would best serve the patient.
Although considerable energy and teamwork are required
to develop and implement a critical pathway, the greatest gains
can come from using these tools as “sensory organs” to
describe variations in the care for patients with a specific
syndrome. Collection of data on when “variances” from a
pathway occur can be used to identify physicians who vary in
practice patterns from their colleagues, or instances in which
the lack of availability of systems resources (e.g., weekend
exercise testing) limits the ability of physicians to apply the
recommended strategy.
In conclusion, the provision of guideline and protocol
information via a high intensity intervention (e.g., person-to-
person feedback) has often been associated with significant
changes in physician behavior for patients with cardiac condi-
tions (28–32). In an environment without direct financial
incentives, the provision of guidelines via written information
and education alone often failed to produce sustained changes
in clinical practice (26,27). These findings in cardiology are
entirely consistent with observations regarding the implemen-
tation of guidelines for other conditions (2,36,37). In general,
high intensity strategies are much more likely to be effective,
while low intensity strategies may have very limited effective-
ness.
Research on practice guideline implementation is ex-
tremely limited. First, many of the studies have focused on
hospital admission rates and length of stay in the acute care
hospital. There is even less information known about the
effectiveness of cardiology guidelines to sustain changes in
patient care unrelated to length of hospital stay. Second, much
of the research has been performed in urban, academic
teaching hospitals. Moreover, the targets of the feedback were
often house staff, who may respond differently to feedback
from an attending physician than a peer (intimidation may
have been a factor). Third, in some studies it is difficult to
disentangle the effects of the guideline from secular trends that
were occurring independently of the guideline. Finally, more
comprehensive studies of patient outcomes are essential. Al-
though length of stay may be reduced, less is known about the
effects of this apparent reduction in costs on other important
patient outcomes, such as discharge location (are patients
discharged to a rehabilitation facility or a nursing home rather
than their own home?), care following discharge from the
hospital, functional status, and patient satisfaction.
Medicolegal Considerations
Practice guidelines represent standards of care, and there-
fore are potentially highly relevant to medical malpractice
litigation in which the issue is whether treatment rendered by
the defendant fell within an appropriate standard of care.
Some health care reform advocates support use of guidelines
as a strategy for decreasing malpractice risk and lowering
health care costs. Since guidelines allow standards of care to be
more clearly articulated, uncertainty surrounding the appro-
priate standard of care can be reduced or even eliminated. This
clarity might help physicians meet the standard of care if the
guideline is implemented effectively, and reduce the need of
physicians to practice “defensive medicine,” whereby costly
tests or procedures that are not medically necessary are
ordered as a defensive posture to a potential medical malprac-
tice suit.
Despite this optimistic assessment, the few data available
suggest that the overall impact of practice guidelines on
malpractice litigation is complex. Guidelines have been used by
both plaintiffs and defendants in malpractice litigation for over
a decade, but only a fraction of medical malpractice cases
come to trial. A recent review of 259 litigation files found that
17 involved the use of practice guidelines, and these guidelines
were twice as likely to be used against the defendant as for the
defendant (38). However, information from guidelines might
also persuade an attorney not to take a case; or lead a plaintiff
to seek an early, lower settlement. Hence, case files provide a
biased assessment of the impact of guidelines.
A more balanced assessment of the impact of guidelines
was provided in the same study (38) through a survey of
approximately 600 attorneys whose area of interest is medical
malpractice. Over 25% of the plaintiffs attorneys claimed that
a factor in their decision not to take a case was the existence of
a guideline favorable to the defendant. A similar proportion
(31%) claimed that guidelines unfavorable to the defendant
influenced them to take a case. Over 25% of attorneys who
responded to the question indicated that they had been
involved in a case that had been settled because of a guideline.
Thus, guidelines appear to be influencing malpractice litigation
in ways both favorable and unfavorable to the defendant and
health practitioner.
Additional data were recently provided by a computerized
search of cases (39) published from 1980 to 1995 that men-
tioned any of the 57 professional societies, agencies, or other
groups that were listed as guideline sources in the 1992 edition
of the American Medical Association’s Directory of Practice
Parameters. This search yielded 52 cases. In 26 cases, guidelines
were used successfully by the plaintiff, and in 8 cases guidelines
were used successfully by the defendant. “Successfully” in this
context does not refer to the ultimate outcome of the case, but
to the fact that the particular issue before the court involving
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standard of care was decided in favor of the party relying on
the guideline as evidence. In the remaining 18 cases, guidelines
were unsuccessfully cited by plaintiffs in 12 cases and defen-
dants in 6 cases. Cardiology societies were not among the
sources of guidelines cited in these cases.
Admissibility of Guidelines Into Evidence
The survey of malpractice attorneys (38) indicated that
guidelines are generally viewed as admissible evidence, but at
least two jurisdictions have specifically disallowed guidelines
on evidentiary bases. For example, in Stang-Starr v. Byington
(248 Neb. 103, 532 N.W.2d 26,28 [Neb. 1995], the court held
that the testimony of the plaintiff’s expert on the contents of an
American College of Obstetrics and Gynecologists technical
bulletin was inadmissible as hearsay. In other words, the court
did not consider the guidelines direct testimony from the
expert panels that had developed the guidelines. However, at
least one court has held, in affirming a directed verdict for the
defendant, that standards admitted into evidence by them-
selves and not through an expert witness do not require that
the standard of care be established by expert medical testi-
mony (McAnn v ABC Insurance Co, No. 93-CA-1789 [La.
App. 1994].
Even if a guideline is admitted as evidence and presented
through an expert witness, a review of case law indicates that
courts will exercise discretion in determining the weight to be
given the guideline in question. For example, in Washington v.
Washington Hospital Center, 579 A.2d 177,182 (D.C. 1990),
the court held that the guidelines constituted the standard of
care—despite arguments by the defendant that the guidelines
of the American Society of Anesthesiologists relied upon by
the plaintiffs were only “emerging,” and were not “mandato-
ry,” but instead “encouraged.” In contrast, in Shuford v.
McIntosh, 104 N.C. App. 201, 408 S.E.2d 747 (N.C. Ct. App.
1991), the court refused to admit a pamphlet entitled “Stan-
dards for Ambulatory Care” into evidence, stating that the
pamphlet appeared to offer recommendations rather than
standards of care.
To date, the absence of recommendations for the use of a
test has not provided protection for defendants against suits
claiming that the test should have been performed (Short v.
U.S., Civ. No. 1:93CV233 [Dis. Vt. 1995]), but the increasing
number of guidelines addressing a wide range of topics may
cause the absence of recommendations to carry greater weight
in the future.
In summary, experience to date indicates that courts vary
markedly in their interpretation and consideration of guide-
lines. Factors that appear to influence the courts’ use of
guidelines include the intent of the guideline and its drafters,
the situation in which it is to be applied, the general acceptance
within the medical community, the cost of compliance, and its
consistency with the existing standard of care. Guidelines
clearly represent a two-edged sword for defendants involved in
malpractice litigation. Available data suggest the certainty of
greater reliance on such guidelines in medical and legal
communities in the future.
Conclusions
Although practice guidelines and critical pathways are
sometimes perceived as a threat to autonomy and intellectual
growth for physicians, they are potentially tools for improving
quality of care. That potential remains incompletely realized,
and can only be achieved through collaboration among spe-
cialty and primary care physicians and other parties in the
health care system. Practice guidelines should never supercede
physician judgment in the care of individual patients; they are
tools that cannot be expected to be relevant to all patients
because of the variability in patients’ problems and prefer-
ences. However, practice guidelines can be useful in discus-
sions between physicians and patients of alternative manage-
ment strategies. Properly developed and applied, practice
guidelines and critical pathways may help physicians enhance
their influence over quality of care.
A variety of methods for guideline dissemination and
implementation have been used. Unfortunately, there is rela-
tively little research to guide us on the most effective methods
by which the goals of guidelines should be achieved. Most of
the evidence that is currently available is based on either an
anecdote or at best systematic observational study. Neverthe-
less, the evidence that does exist provides several general
principles regarding guideline implementation:
1. Physicians appear to prefer guidelines that are simple,
including those which use clinical decision algorithms or
graphs rather than extensive, full-text documents.
2. Guideline implementation strategies that lead to repetitive
exposure and/or reinforcement are more effective in influ-
encing outcomes than those that are simply disseminated
passively without reinforcement.
3. Guidelines that are delivered through opinion leaders are
more likely to be followed than those that do not include
such authorities among their advocates.
4. Practice guidelines supported by evidence from clinical
trials are more likely to be adopted by physicians.
5. The provision of feedback to clinicians on their perfor-
mance is likely to enhance adherence to practice guidelines.
There may be considerable costs involved in the collection
of these data; hence, the variables measured should be
carefully selected, and data collection should be incorpo-
rated into routine processes to the extent possible.
6. The incorporation of practice guidelines into tools involved
in the delivery of routine care (e.g., order sets) will most
likely facilitate their implementation.
7. The major cultural shift that must accompany optimal use
of practice guidelines suggests that their content and theory
should become a major focus of training for physicians and
other health professionals.
8. Provision of information to patients on practice guidelines
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and critical pathways is likely to improve compliance with
pathways and patient satisfaction.
It is also likely that nonclinical factors, including changing
financial incentives or fear of litigation, may play a major role
in determining the impact of guidelines. Unfortunately, data
measuring the impact of these types of incentives are lacking.
These incentives should be addressed explicitly as part of
efforts to implement guidelines in any setting.
Recommendations
● The ACC/AHA should consider strategies, including
possible development of an Implementation Committee,
to support appropriate implementation of practice guide-
lines in cardiovascular medicine.
● The ACC/AHA should develop core data elements to
measure compliance with practice guidelines related to
quality of cardiovascular care, and define the methods for
collection and analysis of these data.
● The ACC/AHA should promote and set standards for
development and implementation of practice guidelines
that
—are available in multiple formats and in simplified
versions to facilitate clinical care, research, and/or
education in the broadest range of settings;
—develop and implement methods for evaluation of
practice guidelines and critical pathways;
—are sufficiently flexible to allow for local modification;
and
—support collection of performance data and documen-
tation.
● The ACC/AHA should take steps to support health care
providers in the development of practice guidelines and
critical pathways. These steps could potentially include
coordination of sharing of pathways among institutions;
critical review of pathways on a clinical topic; or synthesis
of critical pathways on a clinical topic into a strategy
endorsed by the ACC/AHA.
● The ACC/AHA should support the incorporation of
information on and use of practice guidelines into the
training of physicians and other health professionals.
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Task Force 3: Guidelines for Credentialling Practicing Physicians
GEORGE A. BELLER, MD, FACC, CO-CHAIR, WILLIAM L. WINTERS, JR., MD, FACC, CO-CHAIR,
JOSEPH R. CARVER, MD, FACC, SPENCER B. KING III, MD, FACC,
BEN D. MCCALLISTER, MD, FACC, RICHARD L. POPP, MD, FACC
Credentialling and recredentialling of practicing cardiovascu-
lar specialists are emerging as increasingly important activities
of hospitals, health maintenance organizations (HMOs), phy-
sician provider organizations and other medical organizations.
Many of these organizations, as well as insurance companies,
have also developed guidelines for clinical competency, many
of which contain minimal and optimal volume and outcomes
standards recommended for securing clinical privileges to
perform various procedures. Inherent in many of these guide-
lines for credentialling is documentation of specialty or sub-
specialty certification, granted by recognized national organi-
zations such as the American Board of Internal Medicine
(ABIM). Recertification has been undertaken by such organi-
zations more recently to ensure ongoing acquisition of knowl-
edge deemed necessary for providing excellent care. Proce-
dural competency, however, is still predominantly in the
domain of local credentialling and privileging bodies at hospi-
tals, HMOs or other physician-hospital organizations.
In this review, the major issues pertaining to physician
credentialling and privileging are discussed, and recommenda-
tions for possible future initiatives are provided.
There is no doubt that the American College of Cardiology
(ACC), the American Heart Association (AHA) and the
various cardiology and cardiovascular surgery subspecialty
organizations will become more involved in developing guide-
lines for clinical and procedural competency. The national
cardiovascular organizations will be asked to publish compe-
tency standards that are evidence-based and endorsed by
experts. The processes for guideline development in this area,
particularly when new technology emerges, await clearer def-
inition.
Certification Processes
Many U.S. organizations provide certification of profes-
sional accomplishment. The most prominent among those
dealing with physicians is the American Board of Medical
Specialties (ABMS), an umbrella organization comprising 24
independent certifying boards, including the ABIM. The
ABMS certification process is linked to the Accreditation
Council for Graduate Medical Education (ACGME), which
sets standards for residency and fellowship training in each
specialty and subspecialty. Only physicians who finish their
training in programs approved by the ACGME (or the Royal
College of Physicians and Surgeons of Canada or the Profes-
sional Corporation of Physicians of Quebec) can apply for
certification by ABMS boards. The ACC recognizes the ABMS
Boards as the preferred organizations for certification of its
members.
Certification by ABIM recognizes excellence in the disci-
pline of internal medicine, its subspecialties and areas of added
qualification. The ABIM certification process is voluntary; lack
of an ABIM certificate does not prevent one from practicing.
Approximately 86% of those finishing approved residency
training programs are ABIM certified within six years of
completing their training. Indeed, many noncertified physi-
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cians have completed specialty or subspecialty training and are
currently practicing.
The ABIM requires certification in internal medicine prior
to certification in cardiology. Certification in an added quali-
fication, such as clinical cardiac electrophysiology or interven-
tional cardiology, requires a valid certificate in the underlying
discipline of cardiology.
The ABIM works in partnership with the training program
directors, who must verify the requisite training for each
candidate before he or she is admitted to an ABIM certifica-
tion examination. Candidates are rated annually by their
program directors on component skills judged to be essential
to providing excellent care. Candidates whose skills are rated
unsatisfactory by the program director are not admitted to the
ABIM examination (1).
ABIM examinations are valid and reliable and are con-
structed by expert physicians, medical editors and psychome-
tricians. The relevance to practice of each question is rated by
an outside group of practitioners in the discipline (2). The
standard for passing is an absolute score. Examination scores
are positively correlated with program director ratings, and the
practices of certified internists receive higher ratings than do
those of uncertified internists (3).
Whenever the ABIM develops a new certification process
in a new area, there is a five-year period during which
“grandfather” physicians—established experts with little or no
formal training—may apply. After this period, formal training
in an ACGME-approved program is required to sit for a
certification examination.
Although the ABIM does not directly test technical com-
petence in procedural skills, it has worked with program
directors and subspecialty societies to develop a list of proce-
dural skills to be mastered during training. Program directors
must validate the mastery of those skills directly as a prereq-
uisite for certification. For cardiovascular training, ABIM
requires skill in advanced cardiac life support; electrocardiog-
raphy; ambulatory monitoring and exercise testing; echocardi-
ography; cardioversion; arterial catheter insertion; and right
heart catheterization, including insertion and management of
temporary pacemakers. The ABIM does not prescribe the
number of times procedures must be performed to ensure
competency, but “Documentation may be provided by a pro-
cedure card, computer record, or logbook . . .”
The ABIM offers a certificate of “Added Qualification in
Clinical Cardiac Electrophysiology for Diplomates of the Car-
diovascular Diseases Subspecialty Board,” for those who have
completed an additional year of approved electrophysiology
training and who have successfully passed an examination. The
technical skills needed in this field are validated by program
directors who can directly attest to the candidates’ compe-
tence. In the future, the Board will establish a specified
minimum number of electrophysiology procedures for all
candidates. For this purpose, the Board “prefers to use a
uniform set of quantitative standards that is widely endorsed
and accepted by the subspecialty community.”
ABIM certification of the added qualification of interven-
tional cardiology was recently approved by the ABMS. A
specified minimum number of procedures will be required to
establish eligibility. The ABIM and others are investigating the
promise of new techniques that might permit direct testing of
procedural skills.
All ABIM certificates issued after 1990 are time-limited:
The duration of certificates in internal medicine, cardiology,
clinical cardiac electrophysiology and interventional cardiology
is now 10 years. Recertification is required to revalidate
certificates. It consists of three steps: a self-evaluation process,
assessment of clinical competence and a written final exami-
nation (4).
The need for professional standards and the desire on the
part of physicians with special expertise to be recognized has
led to the development of a variety of certification-type
programs outside the ABMS. Some of these programs are
sound; others are flimsy at best. In cardiology, several non-
ABMS groups offer challenging exams for the purpose of
recognizing special expertise. The North American Society for
Pacing and Electrophysiology (NASPE) has given their
NASPExam® for many years. It is a test of knowledge
predominantly regarding cardiac pacing. It is not a certifying
exam; a letter documenting the successful completion is sent to
those who pass.
The American Society for Echocardiography (ASE) has
developed ASEeXAM®, a test of interpretative skills and
knowledge of echocardiography. This test is open to all
physicians. Passing this test results in a certificate of “Special
Competence in Echocardiography.”
The Certification Council for Nuclear Cardiology, an entity
separate from the Society for Nuclear Cardiology, plans to
offer an examination to validate competency in nuclear cardi-
ology techniques. This process will be open to all qualified
physicians (5).
The ACC has responded to the need to improve skills for
electrocardiography by developing an educational process
(ECGSAP) and examination (ECGEXAM) for electrocardio-
graphic (ECG) interpretation. It is available to all physicians.
An individual’s pass/fail status is determined by an absolute
standard and is reported to the examinee. The ACC plans to
reassess this new effort after further experience.
ECGSAP/ECGEXAM is a valuable experiment that is
testing “new waters.” It raises most of the issues central to this
Bethesda Conference and deserves more exploration by the
ACC and, perhaps, the ABIM. For example, traditional eval-
uation bodies such as ABIM are required by the ABMS to
couple certification with at least one year of ACGME-
approved training. This makes cross-specialty recognition of
component technical skills difficult. Development within the
ABMS of common evaluation programs for internists, sur-
geons, family practitioners and emergency physicians, to name
a few with overlapping skills, is therefore problematic. On the
other hand, the ACC traditionally has been an educational
institution and has little experience in processes that could be
considered “certification.”
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Local Hospital Credentialling of Physicians
Overview of the Credentialling Process
The literature in cardiovascular medicine is replete with
descriptions of training program requirements to prepare
cardiovascular specialists for the practice of cardiology. Con-
tent and duration of training programs have long been estab-
lished by the ABIM. Verification of training and skills to satisfy
board-eligibility requirements is provided by training program
directors as well as section and department chairs. Con-
firmation of board certification and, now, recertification—
established by passing specialty board examinations—is pro-
vided by the ABIM on request. This information, available for
every individual completing (or not completing) a cardiology
training program, would provide a local hospital credentialling
committee pertinent information to establish criteria to judge
acceptability of applicants initially applying for hospital privi-
leges.
How often is this information being used by hospitals in the
credentialling process? One might assume it would be applied
universally, to satisfy the credentialling process established by
the Joint Commission on Accreditation of Healthcare Organi-
zations (JCAHO) for hospital medical staffs. This process
reads as follows (6):
The medical staff is responsible for the credentialling process.
This credentialling process includes a series of activities de-
signed to collect relevant data that will serve as a basis for
decisions regarding appointments and reappointments to the
medical staff, as well as delineation of clinical privileges for
individual members of the medical staff. Although the specific
information used to make decisions regarding appointments
and reappointments is at the discretion of the individual
organization, the range of information used should be explicit.
In addition, within, and at the discretion of, an organization, the
specific information required for appointment may differ from
the information required for reappointment. The required
information should include data on qualifications such as
licensure and training or experience, and data on actual per-
formance that is collected and assessed initially in an ongoing
process.
This provides a format for the individual hospital credential-
ling committee to decide what information is used and the
process through which it is passed.
There is very little documentation in the literature as to how
often this process is followed at the local hospital level.
Results of a Survey of Credentialling Processes
What are the practices that hospitals have established for
credentialling and recredentialling in cardiology? Is this pro-
cess data driven? Is it uniformly applied? What information is
used? To answer these and related questions, a survey was sent
to cardiologists at 102 hospitals, 50 of whom were governors or
state chapter presidents of the College. The rest were actively
practicing physicians in academic centers, urban areas (non-
university hospitals), rural towns or cities and Veterans Affairs
(VA) hospitals. Seventy-five responses were obtained: aca-
demic (28), urban (39), rural (6) and VA (2). Table 1 provides
a summary of questions and responses.
Analysis of the information obtained from this survey
provides some general conclusions:
Table 1. Initial Credentialling Process
Academic
(n 5 28)
Urban
(n 5 39)
VA
(n 5 2)
Rural
(n 5 6)
I. Initial General Cardiology Credentialling
1. Hospital credentials committee 27 37 2 6
2. Autonomous: yes 15 27 1 6
3. General cardiology privileges require board eligibility/certification 23 32 1 1
4. Proof of training by
Training director 26 36 2 4
Chief of service 26 36 2 5
5. Does hospital administration participate in documentation 20 34 2 5
6. Approval of hospital privileges by executive committee
and/or board of directors
22 35 2 5
II. Initial Credentialling for Procedural Cardiologists
7. Logs required for training 14 15 2 1
8. Use of national guidelines 16 27 0 5
9. Local modification of national guidelines 22 32 1 5
10. Proof of training 24 37 2 4
11. Adherence to national guidelines for
Echocardiography 17 17 0 1
Echocardiography/Doppler 16 17 0 1
Nuclear cardiology 16 20 0 1
VA 5 Veterans Affairs.
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1. Virtually every institution has a functioning credentials
committee, which in most cases is immune to a department
chair veto. The great majority require candidates to be board
eligible or certified and to provide proof of training. The
institution’s administration almost always participates in the
documentation and granting of privileges, by requiring execu-
tive committee and/or board of director approval.
2. For the procedural cardiologist, the credentialling pro-
cess is similar, but, in about half of responding institutions, also
requires log documentation. Somewhat more than half of
hospitals accept national guideline requirements for proce-
dural training, but a majority of those may modify credential-
ling requirements for their own reasons.
3. For recredentialling, adherence to some interventional
volume requirements for coronary angiography is required in
slightly more than half of institutions responding, with ranges
of 12 to 300 annually (Table 2). The same pattern is true for
percutaneous transluminal coronary angioplasty (PTCA) vol-
ume, except for urban hospitals, 75% of which had no require-
ment. Ranges of 10 to 150 procedures were reported for those
with such a requirement. Some institutions reported volume
requirements for other coronary interventions, including
stents, but more are tied to PTCA privileges. Less than 25% of
hospitals require specific numbers of pacemaker or implant-
able cardioverter-defibrillator (ICD) insertions, electrophysi-
ologic (EP) studies, valvuloplasties, intravascular ultrasound or
peripheral vascular intervention.
A large majority of hospitals require a credentialling pro-
cess for new technology. This process most often consists of
industry courses, in-house training, outcome assessment and
training by peers. Specific outcome assessment was not ad-
dressed.
To maintain procedural credentialling, most hospitals pur-
sue ongoing efforts that include review of number of proce-
dures performed, complication rate, success rate, physician
attitude and tardiness. Volume of procedures as recommended
by national guidelines is loosely utilized, if at all—not surpris-
ing given the heated debate over the concept.
An appeal process for physicians who fail to meet volume
requirements is in place in a majority of hospitals. An open
review process for invasive interventional procedures is in
place at well over half of hospitals, most often with a nurse/
physician assistant (PA) participating. Nearly every institution
has a process in place to deal with the problem physician,
including the potential for decredentialling. Adherence to
medical staff-established clinical pathways for recredentialling
is required in about 20% of hospitals, with another 20%
seriously considering that choice.
Somewhat surprising was that only two-thirds required
continuing medical education (CME) credits to remain cre-
dentialed (although this is often state mandated). None of the
responses reported economic credentialling, and some indi-
cated ignorance of the term. This could be taken to reflect
inexperience with some managed care concepts, but may be a
matter of survey bias.
The survey clearly shows that standards for credentialling
by hospitals vary considerably. For credentialling, attention is
paid to some measure of competence, but the parameters used
to measure competence were not assessed in sufficient detail to
judge their impact on either the general cardiologist or the
interventionalist.
It would be useful to know if current recredentialling
processes utilize outcome parameters that embrace freedom
from adverse medical events, quality of life, patient satisfaction
and cost. Would it be helpful to hospital medical staffs to have
a better defined method for monitoring physician performance
in the periodic recredentialling process? Would they use a
guideline specifically developed to improve the credentialling
process? Should the JCAHO consider modifying its recom-
mendations to medical staff bylaw committees to suggest
credentialling and recredentialling requirements adhere to
published national guidelines? Is there a better way to monitor
performance of cardiologists—general and procedural? (7).
Although this survey suffers from a number of shortcom-
ings, the clear message is that, despite a credentialling process
in nearly every hospital, the information that is required and
the credentialling process itself vary widely—even among
academic institutions.
It is incumbent on cardiovascular practitioners to gather
data that can be used to improve patient care. In our new
environment of accountability, assessment is focused on the
quality of health care delivered. That assessment should start
with the systematic review by each local hospital staff of the
value provided by each individual practitioner, an ongoing
process that embodies the spirit of credentialling and recre-
dentialling and provides the link between “doing the right
things” and “doing things right” (7).
Credentialling by HMOs
In the past, a physician needed only a degree and a valid
license to practice medicine. All one needed to do was find an
office and “set up shop.” Patient volume increased over time,
with ensuing professional and financial success almost guaran-
teed. This typical career path has changed dramatically in the
current era of managed care, which, by definition, alters the
traditional relationship between doctors and patients. Patients
may now be directed to specific primary care and specialty
physicians. The control of patient flow shifts from the individ-
ual and the local physician community to a gatekeeper, who
makes decisions and offers choices based on a list of “partici-
pating” physicians. One of the basic functions of an HMO is to
offer patients a select group of providers. When any panel
comprises “select” participants, it suggests an inherent notion
of meeting certain criteria. What are the rules? Who are the
rule makers? How does one get listed and stay listed? Are
those excluded from listing also excluded from potential
success?
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Types of Managed Care Organizations
Managed care plans generally are classified under three
models, each with different financial risks and incentives,
participation criteria and access to patients:
1. In-staff or group practice HMOs, physicians are gener-
ally salaried employees, with a patient and total provider
population defined within the walls of the HMO.
2. In independent practice association (IPA) HMOs, phy-
sicians practice with some fraction of their patient volume
determined by the HMO. Physician income is a blend propor-
tional to the practice’s payer makeup. They incur some finan-
cial risk for their managed care population with well defined
lines and rules for referral of care and participation.
3. In preferred provider organizations (PPO), a group of
physicians agrees to provide services to a health plan’s mem-
bers according to mutually agreed upon discounted fees.
Criteria to participate are defined loosely by the “mother”
organization, which may be a group of physicians, a hospital, or
a health plan.
Different credentialling criteria from one plan to another
stem largely from the driving philosophy of the plan (economics
vs. quality), plan objectives (restrictive criteria vs. all inclusive),
the maturity of the plan (growing vs. well established and “tight-
ening”) and the economic payment model (fee for service vs.
capitation). In general, quality, tightening and capitation tend to
produce harsher credentialling requirements.
Table 2. Recredentialling Process
Academic
(n 5 28)
Urban
(n 5 39)
VA
(n 5 2)
Rural
(n 5 6)
1. Interventional procedures (no. of procedures required)
Coronary angiography 17 (12–300) 19 (25–300) 0 1 (100)
PTCA 18 (10–75) 9 (10–150) 1 (100) 2 (30)
Other (atherectomy, etc.) 5 9 (10–75) 0 0
Stents 5 (10) 6 (10–25) 0 0
Biopsy 3 5 0 1
Pacemaker 9 (5–25) 9 (5–25) 0 1
ICD 6 (5–10) 2 (10–20) 0 0
EP 8 (30–50) 7 (10–75) 0 0
Peripheral vasc intervention 4 (5–25) 3 (10–50) 0 0
Intravasc US 3 (5–10) 0 0 0
Valvuloplasty 4 (10) 3 (5–10) 0 0
2. Credentialling process for new technology (i.e., stents) 25 29 1 6
3. Does this process include medical 23 32 2 5
Industry courses 23 31 2 5
Inhouse training 23 30 2 5
Outcome assessment 23 26 2 4
Assessment by peers 21 22 2 6
4. To maintain procedural credentialling, is there a review process? What is reviewed? 25 36 2 5
No. of procedures 25 28 2 3
Complications 26 29 2 4
Success 23 27 2 3
Tardiness 18 13 2 1
Attitudes 15 19 2 3
5. With volume requirements, an appeal process for M.D.? 16 19 1 2
6. Hospital quality assessment committee? 28 38 2 6
7. Peer review committee for cardiology? 17 33 0 4
8. Same committee 7 8 — 3
9. Open review process for invasive interventions 22 27 1 3
10. Role for nurse/PA colleagues 22 27 1 3
11. Institutional process for problem physicians 26 36 2 6
12. Decredentialling process? 25 32 2 4
M.D. grievance 23 29 2 3
Patient grievance 18 24 2 3
13. Economic credentialling for physicians 0 0 0 0
14. Local physicians clinical pathway 6 7 0 1
Adherence a requirement for recredentialling? (7)—under study—(7)
15. Are CME credits required? 18 25 1 3
CME 5 continuing medical education; EP 5 electrophysiology; ICD 5 implantable cardioverter-defibrillator; Intravasc US 5 intravascular ultrasound; PA 5
physician assistant; PTCA 5 percutaneous transluminal coronary angioplasty; vasc 5 vascular.
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Credentialling
Physician credentialling is the process by which a health
plan selects and authorizes physicians to provide services to its
members. Competition forces health plans to distinguish them-
selves in cost and the quality of the network that represents
them. The two are exquisitely linked: One of the best methods
to control cost is to control the network of physicians providing
services. This strategy is justified by the credentialling process,
which can produce a double benefit to the health plan and its
members: Choice is limited only by criteria that produce the
largest number of high-quality physicians who can achieve the
necessary cost efficiencies. It has been argued that credential-
ling favorably affects both utilization rates and quality of
service (8).
Response of the Provider Community
Credentialling that is perceived positively by HMOs is
generally perceived negatively by the provider community: It
threatens independence and autonomy, with adverse economic
impacts. Legislative movement to block the ability of health
plans to tailor their networks has led to individual state activity
which attempts to enact “any willing provider” laws. To date, at
least 10 states have approved some form of this legislation.
The American Medical Association (AMA) has recom-
mended stringent conditions to offset provider concerns. These
include removing threshold exclusions, identifying objective
criteria based on professional competence and clinical perfor-
mance and providing due-process procedures for excluded
physicians (9).
At the individual physician level, the requirements of the
credentialling process add a significant administrative burden
and obstacle. Among insurers, credentialling criteria and the
associated documentation and questionnaires are as varied as
the number of health plans. This lack of uniformity must be
addressed and rectified.
From a clinical standpoint, a major argument against
network credentialling and restriction is continuity of care.
Subscribers may join a health plan only to find out that their
doctor does not participate. Even when the doctor wants to
join and meets general criteria, he or she may be excluded
because the “network is closed.”
Other broad arguments against narrowed networks that
result from the credentialling process are limited provider
choice, limited access to the best provider for a particular
clinical problem and an arbitrary limitation to patient volumes.
A final concern is whether HMOs are making decisions based
on incomplete or inaccurate information. For example,
administrative data alone lack clinical markers that are
needed for adjustment based on case mix and severity, as
recently described by Kouchoucos (10). Also, there is no
scientific evidence that restricting panel membership en-
hances quality (11).
Why Credential?
Credentialling by health plans—aside from tailoring a net-
work to meet care outcome and financial goals while meeting
the criteria of oversight organizations—must also address the
alarming frequency of dishonesty that has recently been doc-
umented (e.g., Sekas and Hutson [12]). Similar misrepresen-
tation has been reported in the ACC fellowship process and by
the Washington Post (13), which documented misrepresenta-
tion of physician’s board certification status and other incor-
rect information.
A rigorous credentialling process can also identify problems
revealed, for example, through the analysis of physician deci-
sion making. And an arguably good may result: Recently, a
group of surgeons was identified as having an excessive number
of malpractice actions against them—until it was learned that
every such case was related to a single class action suit for
breast implants. A superficial process may have excluded this
group from participation.
Credentialling Criteria
Various guidelines exist for specialist physician credential-
ling among the HMO communities. This can produce a
hierarchy of conditions and restrictions, ranging from generally
free access of providers in an immature startup marketplace to
extremely restricted access in a tightly controlled mature market
that is fully capitated with a restricted number of physicians. Here,
criteria may extend to board certification, achieving certain
outcomes, and gaining specified CME credits.
In general, there are three stages of network modeling that
influence the credentialling process. Early in the establishment
of managed care in a given market, access and size of the
network are dominant forces. In the second stage, price and
economics are predominant, while the final stage centers on
quality (14). HMOs that stress quality in credentialling are
more often using tools such as the Health Plan Employer Data
and Information Set (HEDIS) criteria, developed and pro-
duced by the National Committee for Quality Assurance
(NCQA). The Foundation for Accountability (FACCT) and
the Agency for Health Care Policy and Research (AHCPR)/
Harvard University’s Computer Needs-Oriented Quality Mea-
surement System (CONQUEST) are developing similar tools
for measurement of physician performance.
For the most part, there are no legal implications and
ramifications of health plan credentialling activities except that
1) HMOs have been immune from Federal antitrust laws; 2)
HMOs have been protected against suit when malpractice
claims involve a quality of care issue; and 3) challenges to
adverse decisions for credentialling have been denied when
criteria are uniformly applied and open to general and peer
review.
Initial Credentialling
The initial credentialling of specialist physicians begins with
verification of training, license, hospital affiliation, Drug En-
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forcement Administration (DEA) license, specialty board cer-
tification or eligibility, history of disciplinary actions, unfavor-
able action by other organizations, history of alcoholism or
drug addiction, practice experience and CME achievements.
Also universally included is a query to the National Practitio-
ner Data Bank (NPDB) and the need to document profes-
sional liability insurance. For many HMOs, this minimal
activity encompasses the entire process and satisfies state
insurance commission requirements; for others, it is a minimal
screening tool. The next level or “qualifying” focuses on more
specific needs and requirements of the individual HMO. This
may include communication skills, computer literacy and staff
association at specific institutions.
The NCQA, in addition to issuing HEDIS, conducts accred-
itation of HMOs in a manner similar to that of the JCAHO for
hospitals. The NCQA’s accreditation guidelines suggest that
health plans visit the offices of high-volume specialists to
review the physical site, the medical record keeping practices
and conformance with the HMO’s standards. The NCQA
requires written guidelines for record keeping and states
appointment availability expectations. This process allows a
certain flexibility, beyond bare document gathering, that can be
used either for inclusion or exclusion of physicians to tailor a
network based on objective measures of performance.
Board certification is not a requirement for NCQA accred-
itation and is not a requirement legislated by any legal body.
However, because it is a mark of specialty accomplishment and
because the purchasers of health insurance frequently ask
about the percentage of a health plan’s participating specialists
who are board certified, certification has been used both as a
marketing tool and a way for HMOs to distinguish themselves
among the competition.
The issue of board certification is highly charged and
controversial. There is clearly no unanimity regarding its
worth. Opponents of required certification cite a recent gov-
ernment report stating that research has failed to show that
board certification results in better care (15).
The ABIM states only that board certification is voluntary.
The American Society of Internal Medicine (ASIM) has taken
the position that board certification does not measure physi-
cian characteristics such as listening ability, time spent with
individual patients, availability to provide care, and so forth. In
lieu of required board certification, the ASIM suggests consid-
eration of continuing medical education, peer review, patient
satisfaction, standing in the community, hospital privileges and
outcomes measurement.
A recent survey found that in 62 managed care organiza-
tions, 701% accept other standards that “would demonstrate
competence in internal medicine as a minimum qualification
for participation,” including more than 65% that accept com-
pletion of training alone (i.e., qualification for board examina-
tion or mere completion of residency).
The Health Care Finance Agency (HCFA) advocates the
most current HEDIS criteria (HEDIS 3.0) with the omission of
board certification as a credentialling measure for primary care
physicians under Medicare. When extended to specialty care
by cardiologists, these measures of quality, access and utiliza-
tion focus on prevention and treatment of coronary artery
disease (CAD). The FACCT’s performance measures similarly
focus on CAD. The CONQUEST data set contains informa-
tion on the treatment of acute myocardial infarction, unstable
angina and congestive heart failure. However, because this
information has not been readily available, the use of perfor-
mance criteria for participation has not been adopted by the
insurance industry for general participation.
The process of granting the authority to provide specific
patient care services is called “privileging.” For hospitals, the
JCAHO requires that privileging “be based on assessment of
applicants against professional criteria specified in the medical
staff bylaws.” Physicians must demonstrate individual compe-
tence for each area of activity. Privileging by most HMOs,
however, relies on hospitals to police the granting of compe-
tency and imposes no criteria beyond the hospital. Some
HMOs have adopted the ACC/AHA volume criteria for the
credentialling of physicians to perform cardiac catheterization
and percutaneous vessel remodeling. Other major insurers
have established “centers of excellence,” largely based on
outcome measurements that have been established and/or data
generated by the National Cardiovascular Network. One HMO
has included a cardiac catheterization film review as a minimal
requirement to perform diagnostic cardiac catheterization.
That same HMO has even provided financial incentives for the
achievement of related performance outcomes, including groin
complications, sequencing of diagnostic and therapeutic cath-
eterization and restenosis rates.
Because there are conflicting comparable volume criteria
(16,17), an attempt by one HMO to set minimal volume
requirements for the performance of open heart surgery
ignited a vehement protest (18).
Although there are published guidelines for echocardiog-
raphy, nuclear cardiology and electrophysiology, the contro-
versy that has resulted from the catheterization guidelines has
impeded the implementation of or the application of criteria to
either laboratories or subspecialists. Recently, the American
Society of Nuclear Cardiology has published suggested guide-
lines for the performance and credentialling of nuclear cardi-
ology (19).
What Do HMOs Currently Do?
In a report published in the New England Journal of
Medicine in 1995, Gold et al. (20) reported the results of a
telephone survey, sponsored by the Physician Payment Review
Commission, that was conducted in 1994 by Mathematica
Policy Research. They found that, among 108 plans in 20
metropolitan areas, plans emphasized “careful selection” of
physicians (71%) as opposed to “prune later” (18%) or “as
broad as feasible” (11%) when forming a network. Thirty-eight
percent of the plans were “tightening the network” (subtract-
ing physicians), while 43% were “widening the network”
(adding physicians). In general, HMOs were more demanding
with requirements for board certification or eligibility, network
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hospital privileges, volume requirements (agreement to take a
predetermined number of patients) and exclusivity (not to
practice outside of the plan).
Regarding economic patterns of care for selection, 61% of
the plans responded that physicians’ previous costs or utiliza-
tion of resources had little influence on their selection; 26%
said these factors had a moderate influence; and 13% said that
they had a large influence. Although reliance on quantitative
information was modest, 63% of the plans took qualitative
information (professional reputation, patterns of care) into
account for initial credentialling.
Virtually all plans verified license and credentials, and all
screened for prior disciplinary actions, substance abuse or
similar actions. More IPAs visited physician’s offices to review
the facility and charting and medical care delivered through a
chart review.
Recredentialling
Most HMOs recredential their specialist physician net-
works on a schedule as short as yearly and as long as five years.
The basic process is similar to the initial credentialling process,
and may be limited to a verification of license, hospital
affiliation, an NPDB query and the validation of professional
liability coverage. The inclusion of measures of patient satis-
faction, performance and outcomes are becoming the rule
rather than the exception. Included in many instances are cost
measures intended to determine cost-effectiveness.
The simplest and least sophisticated measures are strictly
utilization parameters, such as 1) prescribing and referral
patterns; 2) number and type of noninvasive studies ordered
per unique member; 3) average total costs for care for each
patient seen; 4) average length of stay in general and by
specific diagnosis; and 5) readmission rates. Other recreden-
tialling parameters may include such measures as 1) member
and referring physician satisfaction; 2) a review of grievances
and member complaints; 3) contract adherence, which may
include target utilization and quality measures; 4) philosophy
of managed care and cooperation with the health plan; 5)
billing practices beyond pure utilization (e.g., fraudulent bill-
ing, overcoding); and 6) focused chart reviews (e.g., for aspirin
use after myocardial infarction or angiotensin-converting en-
zyme [ACE] inhibitor use in congestive heart failure).
Several recent reviews of performance measurements and
“report cards” (7,21–23) indicate the need for physicians to be
involved in the development, interpretation and implementa-
tion of these tools and for data to be population based and
adjusted for case-mix and severity.
Regardless of the scope of the process and the measures
adopted, the concept of “without cause” must be eliminated, so
that a plan is required to provide the reasons for not recre-
dentialling a physician or physician group. All parameters for
the process must be shared and should result from an interplay
between the health plan and physician advisory groups both for
quality assessment/improvement and credentialling. A well
defined appeal process must be accessible for rejected physi-
cians.
Databases
An HMO is somewhat limited in assembling databases that
go beyond purely administrative measures. The practitioner is
able to collect and store more detailed clinical information that
will help establish needed case-mix adjustment, while measur-
ing variables that are not within the reach of the HMO. For
example, even a sophisticated HMO that can capture labora-
tory and pharmacy data along with bills and encounter data
cannot measure the use of aspirin in acute myocardial infarc-
tion. The latter reflects a measurable quality of care issue that
clearly may separate practices according to behavior.
There is, of course, a cost to collecting data, but the major
outlay is not so much in funding as in a mental and philosoph-
ical appreciation of the worth of the process. This important
component of practice is worthy of the dedication of resources
and personnel to gather, enter, track and analyze the data. The
value of a national database (e.g., the Society of Thoracic
Surgery [STS] or ACC database) cannot be overemphasized.
Other Issues
The credentialling/recredentialling process becomes even
more complicated where physicians assume financial risk and,
therefore, the development and maintenance of the network.
NCQA accreditation is dependent on the continued oversight
of this process. The role of credentialling verification organi-
zations also remains to be defined in the current environment.
The latter represents an attempt to streamline the process,
provide uniformity among various insurers and reduce the
administrative burden and cost to physicians.
Future Efforts
Physicians who deal with managed care organizations on
credentialling and other issues should 1) understand the
environment and appreciate the direction of local HMOs; 2)
develop databases to track key performance measures; 3)
measure individual performance in group practices so that
performance of procedures is restricted to cardiologists with
satisfactory training and outcomes; 4) make communication
between HMOs and cardiologists a high priority; 5) under-
stand business and financial issues; 6) explore the use of
nonphysicians to improve care and overall work flow; 7)
develop proactive disease management programs; and 8) be
involved in decision making with the major local HMOs.
Credentialling is the first step in a relationship with a
managed care organization. It is a misunderstood and under-
utilized resource in building a quality system that should never
become an end in itself.
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Role of Professional Societies in Developing
Credentialling Guidelines
Medical professional organizations have developed practice
guidelines for clinical competence in procedural skills for a
variety of reasons, the foremost being to sustain high-quality
patient care. This can provide reassurance to patients under-
going procedures deemed to require certain skills and experi-
ence. Also, hospitals and other institutions providing clinical
privileges to physicians cannot assume that residents or fellows
have received even the minimum training required to perform
certain procedures (24). Clinical competence statements en-
dorsed by reputable professional organizations are welcomed
by hospitals and managed care companies to guide them in
establishing a fair and valid credentialling process for physi-
cians seeking privileges to perform procedures.
Medical organizations also get involved in the guideline
process for credentialling for competence because members
demand such involvement to sustain a high procedural success
rate with a low rate of complications and good long-term
outcomes. Guidelines generated by medical professional orga-
nizations are also educational: They are consensus documents
summarizing indications and contraindications; anticipated
complications, with information on how to manage them; and
how results should be interpreted. In order not to appear
self-serving (i.e., limit the number of operators to reduce
competition), members of specialty organizations base guide-
line methodology on published scientific data and expert
opinion that will be beyond criticism by those excluded by their
inadequate training.
History of ACP/ACC/AHA Guidelines
From June 1990 to May 1995, a task force consisting of
representatives of the ACC, the AHA and the American
College of Physicians (ACP) published a series of guidelines
for clinical competency for a variety of cardiovascular proce-
dures. These were published simultaneously in the Journal of
the American College of Cardiology, Circulation and the Annals
of Internal Medicine as “ACP/ACC/AHA Task Force State-
ments.” These guidelines were intended to define the mini-
mum education, training and experience required to attain the
cognitive and technical skills necessary for the competent
performance of these procedures. Whenever possible, these
procedure-specific guidelines were based on published data.
When data were lacking, a consensus of expert opinion was
undertaken.
The procedures addressed by the ACP/ACC/AHA Task
Force were hemodynamic monitoring, adult echocardiography,
PTCA, exercise testing, electrocardiography, ambulatory elec-
trocardiography and elective direct current cardioversion (25–31).
Background
Prior to this joint effort of the three societies to develop
guidelines for clinical competency, the ACP published a series
of Statements on Clinical Competence developed by the
College’s Clinical Privileges Project Steering Committee. In
1987, the ACP published a position paper entitled, “Guide for
the Use of American College of Physicians Statements on
Clinical Competence” (32). In this guide, the ACP declared
that the Statements of Clinical Competence were intended to
“set forth the minimum criteria necessary for competent
performance of specific procedures and . . . to facilitate assess-
ments of physician competence during the course of privilege
delineation decisions” (32).
Table 3 summarizes the four alternative pathways to pro-
cedural competence proposed by the ACP in the published
guide for use of the ACP statements (32).
In its guide for the use of the clinical competence state-
ments (32), the ACP was careful to point out that the
statements may need to be modified over time, particularly
when research better defined the relationship between proce-
dural competence and physician education, training and expe-
rience. Furthermore, it was emphasized that the number of
procedures performed should not be the sole criterion to attain
competence, but “rather should be considered along with
cognitive skills and educational experience.” The latter is
reflected by the “qualities of the educator” and the “educa-
tional milieu” in which experience with the procedure was
acquired. The guide acknowledged the concept that some
physicians may require considerably more experience to
achieve procedural competence than others due to differences
in manual dexterity. It also noted that the statements cited are
minimum, suggested standards for attaining competence. Fi-
nally, the ACP said that the guidelines were intended to be
applied on a “case-by-case basis in the context of well-defined
privilege delineation and peer review processes.”
In an accompanying editorial (33), Eugene Hildreth, who
chaired the ACP committee that commissioned the clinical
competence statements, wrote that the procedural competence
guidelines were to be neutral as possible in terms of medical
specialty, geographical location and type of practice. He stated
that the ACP’s position was that the guidelines were intended
to “describe minimum competence for the beginner doing the
Table 3. Pathways to Procedural Competence*
● A physician who completes an accredited residency or fellowship program
may achieve certification in the respective specialty, which implies that the
physician’s procedural skills and competence have been documented in
writing
● A physician may successfully complete an accredited residency or fellowship
program in which procedural competence may be documented, independent
of certification
● A physician may successfully complete an accredited residency or fellowship
program in which the procedure is taught, but the physician’s procedural
competence is not documented in writing, necessitating special evaluation
by, for example, inquiry to the program directors or direct observation of
such skills by the credentialling institution
● Due to changes in practice or technology, a physician may become skilled
in a procedure subsequent to his or her formal training
*From reference 32.
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procedure in the average patient.” Guideline development
involved a search of pertinent literature and obtaining expert
opinion, both from those using the procedure in academic
settings and from clinicians. The ACP also sought “coopera-
tion” with other organizations sharing their “common goals.”
Interestingly, Hildreth suggested in this editorial published in
1987 that other organizations, such as “managed care health
systems,” would find the guidelines of value.
The initiative between the ACP and the ACC and AHA
naturally followed the ACP activities for developing guidelines
for clinical/procedural competence. This earlier effort by the
ACP did not include cardiovascular procedures. The rationale
cited for developing guidelines for cardiovascular procedural
competence by the three organizations was that selective
granting of clinical staff privileges to physicians continued to be
one of the primary mechanisms used by institutions to sustain
the quality of care.
Each set of guidelines was written by either a single lead
author or a writing group of no more than two or three
authors. The Task Force members provided critical editorial
review, after which the statements were sent to outside experts
for further comments. Ultimately, the competency statements
were approved by the ACC Board of Trustees, the AHA
Steering Committee and the ACP Board of Regents. They
were then published for use by the ACC membership, each
hospital staff responsible for clinical privileges and the medical
profession as a whole.
Strengths of the ACP/ACC/AHA Guidelines
The positive features or strengths of the joint guidelines are
that 1) they include a descriptive “overview” of the given
procedure; 2) indications, contraindications and complications
of the procedure are succinctly detailed, often in tabular form;
3) a justification for the recommendations is presented; 4)
training in the acquisition of cognitive skills as well as in the
technical skills for the procedure is deemed important; 5)
trainees learning to perform a procedure are required to be
supervised by an effective teacher who is considered an expert
in the clinical use of the procedure; 6) completion of a
fellowship by itself is not acceptable in guaranteeing compe-
tency in the procedure; 7) physicians in private practice are
permitted to achieve the necessary experience to gain compe-
tency in a new procedure by attending courses, workshops,
completing preceptorships and undergoing “supervised practi-
cal experience”; 8) they suggest that cognitive and technical
skills of candidates be confirmed in writing by the training
supervisor or by observation of the candidate doing the
procedures by a physician considered an expert teacher; 9)
they encourage trainees to keep logs during training, docu-
menting the date of the procedure, patient identification
number, indications, findings and signature of the supervisor;
10) they provide recommendations for numbers of procedures
that are required on an annual basis for ensuring continuing
competency; 11) they suggest that quality assurance programs
randomly sample certain procedures (e.g., echocardiograms)
done by a physician be reviewed periodically to confirm that
indications were appropriate, that the examination was ade-
quate for interpretation, that the interpretation of test of
procedural data was accurate and that the results were accu-
rately recorded and shared with other physicians; 12) they
recommend ongoing correlation of results of certain proce-
dures with results of other techniques and the patient’s clinical
course; 13) they recognize that not all training or practice
environments are the same and that a greater or smaller
number of procedures other than the number recommended in
the guidelines may be deemed appropriate by a local creden-
tials committee; and 14) they encourage timely institutional
reviews of patient outcomes after therapeutic or invasive
procedures.
Weaknesses or Limitations of the
ACP/ACC/AHA Guidelines
Some weaknesses or limitations of the ACP/ACC/AHA
Task Force statements have also been identified. Perhaps the
most controversial aspect of the procedural guidelines is
related to lack of objective data from the literature at that time
to support the numbers of procedures that were recommended
as the minimum to attain competency or the numbers judged
as the minimum to sustain competency. (More data are now
emerging which do suggest a link between procedural volumes
and outcomes.) Also, the ACP representatives often proposed
lower numbers of procedures to serve as the minimum to attain
competency, compared to the higher numbers recommended
by representatives of the ACC and AHA. This resulted in delay
in approving certain statements and ultimately required agree-
ment on a compromise number. For example, many cardiolo-
gists perceive that the 800 ECGs recommended for interpre-
tation by the Task Force is too low for attaining true
competency, but this was the compromise number that was
ultimately published (31). A similar difference occurred in
determining the minimum number of exercise stress tests
deemed necessary.
Numbers have also been controversial in guidelines di-
rected solely to cardiovascular specialists. This is best illus-
trated by disagreement over the recommendation that 75
coronary angioplasty procedures should be performed annu-
ally for continuing competency (27).
Another limitation of the guidelines is that they conflict at
times with recommendations made by other professional or-
ganizations, particularly those of the subspecialty societies,
which often state higher numbers of procedures for achieving
competency. This leads to provider and institution confusion.
Certain guidelines that relate to procedures performed solely
by cardiologists should perhaps be generated jointly by the
ACC, AHA and the relevant subspecialty society whose mem-
bers are identified as predominantly performing the procedure
under study.
Local institutional credentialling committees often ignore
the recommendations outlined for competency since the major
aim of a hospital administration is to have as many physicians
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on its staff as possible. Many hospitals do not use the Task
Force recommendations for competency in granting privileges.
Another limitation of the ACP/ACC/AHA guidelines is the
failure to articulate the need for an adequate case-mix during
physician training (34). This can lead to suboptimal training,
even when the requisite number of procedures was performed
by the trainee during training. Eisenberg et al. (34) suggest
establishing minimum criteria for defining an adequate case-
mix for physicians being trained in advanced procedures.
Procedural Guidelines
Procedural guidelines should be, as much as possible, data
driven. Established therapies with support of randomized trials
or overwhelming clinical evidence should be publicized, and
compliance should be measured. Where data are lacking, there
is no choice but to develop guidelines from broad experience,
with the help of the social sciences best efforts to measure
behavior and uncontrolled outcomes.
Guidelines should be just that; inappropriate use of guide-
lines as minimum standards should be discouraged.
Developers of guidelines should be representative of both
expertise in the field and of practitioners representing the field
broadly.
Should Societies Participate in the Development
of Guidelines for Procedure Volumes for
Clinical Competency With Respect to Individuals
and Institutions?
Because guidelines will be developed with or without
specialist participation, it is incumbent on societies to evaluate
the evidence and make reasonable judgments on behalf of its
membership—if only to counterbalance guidelines developed
by others.
Institutional and individual volume measures are better
established for some procedures than others. For some rapidly
changing technologies, it may be impossible to obtain data to
support volume requirements for related procedures. Volume
requirements should be general requirements for subspecialty
areas and not for specific procedures, such as number of stent
placements, number of Swan-Ganz catheter insertions or
number of pericardiocenteses. Guidelines to establish volume
measures should be aimed at improving patient outcomes,
both short and long term, while allowing adequate accessibility.
Is There a Relationship Between Procedure
Volumes and Outcomes for Institutions and
Individuals as Has Been Established for Surgery?
Data suggesting a relationship between institutional and
operator volumes and outcomes of interventions are accumu-
lating (35–41). Institution-specific data have suggested that
less than 200 cases/year are associated with a higher risk of
emerging coronary artery bypass graft surgery (CABG) (36) or
major complications (35) or mortality (37). Operator-specific
data from single institutions (38,39), the Medicare database
(40) and high volume centers (41) show that complications of
intervention are higher among the lower volume operators.
Ellis et al. (41) showed that, as a group, operators performing
less than 70 angioplasty cases/year in high volume academic
centers had a higher complication rate. In complex lesions, the
lowest complication rate was achieved by operators performing
more than 200 cases/year. Jollis et al. (40) found a correlation
between operator volume and complications in the Medicare
database and suggested that a volume of .100 procedures/
operator per year was significantly associated with lower death
or bypass surgery rates. However, in these studies not all low
volume operators had the least favorable results. The data
available have been obtained in a rapidly evolving field, and
more observations are clearly needed.
What Should the Mechanisms Be for Credentialling
Procedural Skills, Both Initially and With Respect
to Ongoing Competency?
The ACC has issued two sets of recommendations for initial
training related to PTCA and catheterization; the Society for
Cardiac Angiography and Interventions (SCAI) has also made
recommendations. At least one year of training for those
entering interventional cardiology in 1996 and beyond has
been recommended. The ABIM has approved, and the ABMS
has endorsed, a certificate of added qualification (CAQ) for
interventional cardiology. This will set minimum training stan-
dards for eligibility to take board certification and recertifica-
tion examinations. It is likely that the ACC will accept these
standards, because the College and the SCAI were the spon-
soring organizations for this action. Electrophysiology has
already gone through this process, and a CAQ is in place.
Regarding specific techniques or use of specific devices,
industry currently provides training and certification for selling
instruments for use by approved physicians. This consists in all
cases of one day or less of instruction, followed in some
instances by proctoring for one to three cases by someone
already credentialed. This is obviously not adequate training
for competency. The ABIM training programs may provide
training in specific devices for those already practicing and
certainly must provide such training for those in the formal
training program. Industry will continue to be involved, and
the role of the ACC in collaborating with industry on training
in new devices needs to be defined.
How Should Database Registries Be Used for
Benchmarking for Procedural Guidelines With
Respect to Outcomes?
The key here is to arrive at common definitions, accurate
and complete data collection and wide participation in data-
bases. The ACC database is best structured to study these
subjects. Risk adjustment and local requirements can be
considered in benchmarking. Use of the data to improve
patient outcomes for all constituents of the College must be
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appreciated by the participants for this effort to succeed. If left
to those for whom economic imperatives are central, bench-
marking may look quite different. The recently reported ad-
verse outcome for intensive care patients receiving Swan-Ganz
catheterization is an example of outcomes research that caused
major confusion. The interpretation of this study raises impor-
tant issues regarding the danger of sweeping conclusions being
drawn from incomplete data (42).
Physician-Specific Report Cards
In order for patients, referring physicians and payers to
make appropriate quality-based selections of health care,
and for physicians to demonstrate accountability for the care
they provide, information concerning the performance and
outcomes of individual practicing physicians is essential
(21,43,44). In addition, objective criteria are needed to guide
managed care programs and other payers in their selection and
rejection of physicians; the current selection is driven primarily
by economic considerations (45,46). Furthermore, in order to
develop objectivity in the credentialling and recredentialling
process necessary and standard at many hospitals, accurate
data are required to benchmark physician staff in relation to
their own colleagues as well as in relation to regional and
national standards (47). Physician outcomes are presently
measured by governmental agencies (i.e., the NPDB, HCFA,
New York State and Pennsylvania Departments of Health), by
managed care companies, by professional societies, by propri-
etary companies and by hospitals and institutions (48,49).
Traditionally, the results of procedural physicians have
been scrutinized, used for credentialling and, in some in-
stances, reported in the public domain (10,18,50–52). A focus
on procedures has developed because of a perception that
these activities have higher costs, morbidity and mortality
(specifically, for cardiac surgery and interventional cardiology).
Recently, HCFA/Medicare and managed care plans have also
been concerned about physician utilization of diagnostic pro-
cedures (e.g., nuclear and ultrasound imaging and cardiac
catheterization), as well as the evaluation of physician profiles
related to the costs of managing specific conditions, such as
chest pain and acute myocardial infarction. In fact, Medicare/
HCFA and some managed care systems have developed com-
parative though non–risk-adjusted profiles, which can provide
an analysis of the billing practices of individual physicians (46).
Physician profiles of humanistic outcomes as well as clinical
outcomes are of increasing interest to patients. Yet, managed
care administrators and physicians with increasing financial
risk may continue to be more interested in economic outcomes
(53).
The Cooperative Cardiovascular Project (CCP) has at-
tempted to measure quality of care by studying the perfor-
mance of groups of hospital physicians by reporting the use of
aspirin, beta-blockers and ACE inhibitors, as well as the time
to reperfusion in patients with an acute myocardial infarction
(54). In addition, the frequency of the use of anticoagulant
therapy in patients with atrial fibrillation has been analyzed.
Critical pathways have been developed, using practice guide-
lines, to guide the management of patients with congestive
heart failure, myocardial infarction and unstable angina. As-
sessment of an individual physician’s use of practice guidelines
and the subsequent effect on length of stay and utilization of
resources will be measured. Of concern is potential overregu-
lation of the complex process of clinical decision making, which
could override clinical judgment in the management of an
individual patient.
Medical outcomes are often difficult to measure, and cer-
tain end points are subjective (e.g., the incidence of myocardial
infarction, procedural success following coronary angioplasty)
and are susceptible to manipulation (7,55). The predictive
capacity of various models, for example, to assess differences in
physician outcomes following coronary angioplasty, have been
modest (55). Furthermore, the low incidence of adverse end
points following coronary angioplasty inhibits the ability to
accurately assess the relation between a poor outcome and
procedural volume, particularly for those physicians with a low
volume of cases (7,55).
In the past, outcome measurements have focused primarily
on early and, in some instances, late freedom from adverse
clinical events. In addition, evaluations of the cost of care,
patient satisfaction, appropriateness and utilization of re-
sources and quality of life measures are of increasing interest
to the medical industry (56). Longitudinal analysis of outcomes
may be particularly important in comparing one physician’s
results with another’s (7). Assurance that patients are not
deselected for appropriate care because of the disincentive
policies of managed care programs needs continued surveil-
lance. High-quality outcome data are essential; volunteer
reporting without auditing has inherent problems with bias and
potential misrepresentation. Methods to standardize risk ad-
justment for severity of illness must be refined (7). In order to
assure clinical relevancy and accuracy, careful medical peer
review of data is essential.
Report cards have been released for public scrutiny and
information by New York State and Pennsylvania, with the
laudable goal of improving quality of care (48,49). Criticism
and justification of the New York State method of public
disclosure have been published (56,57) and at times sensation-
alized by the media. Critics have questioned the validity of the
data, accuracy of reporting and interpretation of results (56).
In addition, fears of “gaming the system” by upcoding, avoid-
ing the treatment of high-risk patients (by referring them out
of state, which could promote a defensive medical posture
practice), misuse of the data by the media and premature
release of the data before careful peer review have been of
concern (56).
However, proponents of the New York State program have
made the compelling argument that the statewide mortality
following CABG has in fact improved significantly, with a 41%
decline in risk-adjusted operative mortality from 1989 to 1992
(57). In New York, the public release of information detailing
risk-adjusted operative mortality—both for patients and insti-
tutions when compared with the state average—has been
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viewed as one part of a strong oversight program that includes
active consultation and advice to outlier programs identified as
performing poorly. There is clearly a continuing need to
educate the public and media in order to prevent misuse of the
data and to prevent sensational or misleading interpretations.
Recommendations
Certification processes:
1. The ACC should recognize and support the importance
and requirement of appropriate training in RRC approved
programs as essential to the certification process.
2. The ACC should work with ABMS Boards wherever
possible and with appropriate subspecialty societies to provide
standardized, objective assessment of skills (cognitive, inter-
pretive, procedural) where needed.
Local-level physician credentialling:
1. The ACC should take a leadership role in developing
recommendations for the credentialling and recredentialling
process to assist hospitals or other institutions. The goal is to
better guide those responsible for local credentialling toward
more objective and effective means for assessing quality of care
delivery in the short and long term (i.e., education as to the
how and why of data collecting systems and other benchmark-
ing techniques in measuring physician-specific performance).
2. Prospective studies or surveys should be conducted to
assess whether formal, rigorous credentialling processes uti-
lized by certain hospitals or networks yield better patient
outcomes for diagnostic and therapeutic cardiovascular proce-
dures.
3. The ACC should encourage the development of a
database/registry in order to facilitate credentialling by the use
of audited, objective risk-adjusted data.
Credentialling by HMOs:
1. The ACC should encourage collaboration with the
health care industry in the development of valid performance
measures to credential practicing physicians.
2. The ACC should take a leadership role in helping
physicians and institutions provide valid data in order to
measure their performance.
3. Credentialling and recredentialling by the insurance
industry should be based on a combination of objective,
case-adjusted measurements of outcome rather than on eco-
nomics.
Role of professional societies in developing
credentialling guidelines:
1. The ACC, in collaboration with the AHA and the
cardiology and cardiovascular surgery subspecialty societies,
should remain engaged in the development and revision of
guidelines for clinical competence in procedural skills.
2. The ACC should utilize its database information and
published literature to generate standards of care, which
should include minimum expected procedural-related mortal-
ity and morbidity rates and other risk-adjusted outcomes. This
will permit dissemination of objective criteria for institutional
QI programs related to operator credentialling.
3. Guidelines for clinical competence should include indi-
cations and contraindications for procedures as well as ex-
pected success and complication rates.
4. The ACC should work with those subspecialty societies
(e.g., NASPE, ASNC, ASE, SCA and SCAI) which seek to
enhance quality of procedural performance and interpretation
of data with examinations to test knowledge and skills in the
given procedural field.
5. The ACC should continue to work with program direc-
tors of fellowship programs and the ABIM Cardiovascular
Board to develop guidelines for trainees, including recom-
mending numbers of procedures and numbers of months
required to attain initial competency.
6. It is not necessary that the ACC, the AHA and the
subspecialty cardiovascular societies publish joint competency
guidelines with generalist organizations for cardiovascular
procedures predominantly or exclusively performed by cardio-
vascular specialists. However, endorsement of such guidelines
by those organizations would be desirable.
7. The ACC should continue to collaborate with noncardi-
ology physician organizations to develop credentialling re-
quirements for those cardiac procedures also performed by
noncardiologists. The minimal volume criteria for attaining or
sustaining competency for such procedures by noncardiologists
should not be lower than those established for cardiologists.
Procedural guidelines:
1. The ACC and AHA should develop guidelines for
performance of procedures done by cardiologists only. The
ACC and AHA with the cardiovascular specialty societies
should cooperate with broader representation for performance
of procedures by other physicians.
2. Research to evaluate the effect of procedure volume on
risk-adjusted outcomes should be encouraged.
3. Health care organizations may use board exams and
CAQs as a measure of excellence. Although these exams are
not a measure of minimal competence, they could serve as a
benchmark for setting standards.
4. Criteria utilized for assessment of ongoing competence in
procedures by the local credentialling body should include the
ACC/AHA Guidelines.
Physician-specific performance measures
The conferees recognize that it has become increasingly
important for hospitals and others to evaluate both institution
and physician performance. Yet it was also recognized that the
process needs further refinement in view of its present imper-
fections and limitations, including the need to develop longi-
tudinal measurement of quality. Conferees further recognize
that data must be risk-adjusted and validated by reliable audits
and must remain confidential. We therefore offer the following
recommendations:
1. The ACC should take a leadership role in the develop-
ment and facilitation of methods to evaluate physician-specific
and institutional performance. This is necessary so that the
process can be studied in order to understand whether these
techniques are in fact a reliable method to measure quality.
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2. The ACC is encouraged to develop a National Database
Registry, so institutions and physicians can benchmark their
performance against national peer-reviewed data.
3. It is appropriate that physician-specific data be used by
hospitals, health care plans and government agencies to cre-
dential and benchmark physicians—provided that the data are
carefully audited, risk-adjusted and verified by appropriate
medical review.
4. The ACC should encourage research on quality outcome
measurements, including methods to monitor managed care
organizations and others who measure physician performance.
5. The release of institutional physician-specific data from
any source must be appropriate, impeccably accurate and used
to educate physicians regarding their performance, in order to
promote improved outcomes.
6. The ACC should continue to develop practice guidelines
in order to enhance the clinical practice of cardiovascular
medicine and surgery and to enhance the development of
indicators to more accurately measure outcomes. These guide-
lines should serve as a standard for clinical practice and for
evaluating physician performance.
7. The ACC should collaborate with the STS to develop
methods to evaluate physician performance.
References
1. Policies and Procedures. Philadelphia: American Board of Internal Medi-
cine; 1995.
2. Norcini JJ, Day SC, Grosso LJ, Langdon LO, Kimball HR, Popp RL,
Goldfinger SE. The relevance to clinical practice of the certifying examina-
tion in internal medicine. J Gen Intern Med 1993;8(2):82–5.
3. Ramsey PG, Carline JD, Inui TS, Larson EB, LoGerfo JP, Wenrich MD.
Predictive validity of certification by the American Board of Internal
Medicine. Ann Intern Med 1989;110(9):719–26.
4. Recertification Program. Philadelphia: American Board of Internal Medi-
cine; 1995.
5. Policies and Procedures. Bethesda, MD: Certification Council for Nuclear
Cardiology; 1996.
6. Credentialling: Comprehensive Accreditation Manual for Hospitals. Joint
Commission on Accreditation of Healthcare Organizations; 1965; p. 510.
7. Califf RM, Jollis JG, Peterson ED. Operator-specific outcomes. A call to
professional responsibility. Circulation 1996;93(3):403–6.
8. Zalta E. Provider selection standards as a quality indicator. Manag Care Q
1993;1(1):53–61.
9. Romeo NC. Why oppose any willing provider legislation? AAPPO J
1994;4(6):19–22.
10. Kouchoukos NT. Quality initiatives and the power of the database: where we
stand. Ann Thorac Surg 1995;60(5):1526–9.
11. Snyder JW. Update on economic credentialing. Hosp Physician 1995;3(6):
47–51.
12. Sekas G, Hutson WR. Misrepresentation of academic accomplishments by
applicants for gastroenterology fellowships. Ann Intern Med 1995;123(1):
38–41.
13. Boodman S. What do the certificates on your doctor’s wall really mean? The
Washington Post 1994.
14. Frieden J. Should employers make physicians account for costs? Bus Health
1992;10(3):40–2, 44, 46–8.
15. Health care reform “report cards” are useful but significant issues need to be
addressed. Report to the Chairman, Committee on Labor and Human
Resources, U.S. Senate. Health care Report Cards. GAO/HEHS ed. Wash-
ington, DC: General Accounting Office; 1994; p. 94–219.
16. Hannan EL, Siu AL, Kumar D, Kilburn HJ, Chassin MR. The decline in
coronary artery bypass graft surgery mortality in New York State. The role
of surgeon volume. JAMA 1995;273(3):209–13.
17. Clark RE, et al. Outcomes as a function of annual coronary artery bypass
graft volume. Ann Thorac Surg 1996;61:21–6.
18. Crawford FA, Anderson RP, Clark RE, Grover FL, Kouchoukos NT,
Waldhausen JA, Wilcox BR. Volume requirements for cardiac surgery
credentialing: a critical examination. The Ad Hoc Committee on Cardiac
Surgery Credentialing of The Society of Thoracic Surgeons. Ann Thorac
Surg 1996;61(1):12–6.
19. DePuey E, Borer J, Brown K, et al. Cardiovascular nuclear medicine training
guidelines. J Nucl Med 1994;35:169–78.
20. Gold MR, Hurley R, Lake T, Ensor T, Berenson R. A national survey of the
arrangements managed-care plans make with physicians. N Engl J Med
1995;333(25):1678–83.
21. Topol EJ, Califf RM. Scorecard cardiovascular medicine. Its impact and
future directions. Ann Intern Med 1994;120(1):65–70.
22. Epstein A. Performance reports on quality—prototypes, problems, and
prospects. N Engl J Med 1995;333(1):57–61.
23. Auder AM, Scott HD. The oversight of medical care: a proposal for reform.
Ann Intern Med 1994;120:423–31.
24. Wigton RS. Training internists in procedural skills. Ann Intern Med
1992;116(12 Pt 2):1091–3.
25. Clinical competence in hemodynamic monitoring. A statement for physi-
cians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardi-
ology. J Am Coll Cardiol 1990;15(7):1460–4.
26. Popp RL, Winters WL Jr. Clinical competence in adult echocardiography. A
statement for physicians from the ACP/ACC/AHA Task Force on Clinical
Privileges in Cardiology. J Am Coll Cardiol 1990;15(7):1465–8.
27. Ryan TJ, Klocke FJ, Reynolds WA. Clinical competence in percutaneous
transluminal coronary angioplasty. A statement for physicians from the
ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll
Cardiol 1990;15(7):1469–74.
28. Schlant RC, Friesinger GC, Leonard JJ. Clinical competence in exercise
testing. A statement for physicians from the ACP/ACC/AHA Task Force on
Clinical Privileges in Cardiology. J Am Coll Cardiol 1990;16(5):1061–5.
29. Clinical competence in ambulatory electrocardiography. A statement for
physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in
Cardiology. J Am Coll Cardiol 1993;22(1):331–5.
30. Clinical competence in elective direct current (DC) cardioversion. A state-
ment for physicians from the ACP/ACC/AHA Task Force on Clinical
Privileges in Cardiology. J Am Coll Cardiol 1993;22(1):336–9.
31. Fisch C. Clinical competence in electrocardiography. A statement for
physicians from the ACP/ACC/AHA Task Force on clinical privileges in
cardiology. J Am Coll Cardiol 1995;25(6):1465–9.
32. Health and Public Policy Committee, American College of Physicians. Guide
for the use of American College of Physicians statements on clinical
competence. Ann Intern Med 1987;107(4):589–91.
33. Hildreth EA. A new look at clinical privileges for procedures. Ann Intern
Med 1987;107(4):585–7.
34. Eisenberg MJ, Rice S, Schiller NB. Guidelines for physician training in
advanced cardiac procedures: the importance of case mix. J Am Coll Cardiol
1994;23(7):1723-5.
35. Kimmel SE, Berlin JA, Laskey WK. The relationship between coronary
angioplasty procedure volume and major complications. JAMA 1995;
274(14):1137–42.
36. Ritchie JL, Phillips KA, Luft HS. Coronary angioplasty. Statewide experi-
ence in California. Circulation 1993;88(6):2735–43.
37. Jollis JG, Peterson ED, DeLong ER, Mark DB, Collins SR, Muhlbaier LH,
Pryor DB. The relation between the volume of coronary angioplasty
procedures at hospitals treating Medicare beneficiaries and short-term
mortality. N Engl J Med 1994;331(24):1625–9.
38. Hamad N, Pichard AD, Lyle HR, Lindsay J Jr. Results of percutaneous
transluminal coronary angioplasty by multiple, relatively low frequency
operators: 1986-1987 experience. Am J Cardiol 1988;61(15):1229–31.
39. Shook TL, Sun GW, Burstein S, Eisenhauer AC, Matthews RV. Comparison
of percutaneous transluminal coronary angioplasty outcome and hospital
costs for low-volume and high-volume operators. Am J Cardiol 1996;77(5):
331–6.
40. Jollis JG, Peterson ED, DeLong ER, Stafford JA, Muhlbaier LH, Mark DB.
Relationship between physician angioplasty volume and outcome in 97,000
elderly Americans [abstract]. Circulation 1996;94 Suppl I:I–532.
41. Ellis SG, Weintraub WS, Holmes DR, Block PC, Shaw RE, Whitlow PL.
Should performance of PTCA at a high volume center ameiorate concerns
1161JACC Vol. 29, No. 6 BELLER ET AL.
May 1997:1125–79 TASK FORCE 3
regarding quality of low volume operator results? [abstract]. Circulation
1995;92 Suppl I:I-73.
42. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart
catheterization in the initial care of critically ill patients. JAMA 1996;
276(11):889–97.
43. Dauphinee WD. Assessing clinical performance. Where do we stand and
what might we expect? JAMA 1995;274(9):741–3.
44. Beller GA, Cohen J. Association of American Medical Colleges 1996:57–99.
45. Brook RH. Health care reform is on the way: do we want to compete on
quality? Ann Intern Med 1994;120(1):84–6.
46. Blum JD. Economic credentialing moves from the hospital to managed care.
J Health Care Finance 1995;22(1):60–71.
47. Topol EJ, Block PC, Holmes DR, Klinke WP, Brinker JA. Readiness for the
scorecard era in cardiovascular medicine. Am J Cardiol 1995;75(16):1170–3.
48. Albany, NY: New York State Department of Health; 1993.
49. A Consumer Guide to Coronary Bypass Surgery 1993. The Pennsylvania
Health Care Cost Containment Council; 1993.
50. Douglas JS, Levin DC, Pepine CJ, Mullins CE, Block PC, Nissen SE, Brinker
JA, Topol EJ, Johnson WL, Ullyot DJ. Recommendations for development
and maintenance of competence in coronary interventional procedures.
American College of Cardiology Cardiac Catheterization Committee. J Am
Coll Cardiol 1993;22(2):629–31.
51. Cowley MJ, Faxon DP, Holmes DR Jr. Guidelines for training, credential-
ing, and maintenance of competence for the performance of coronary
angioplasty: a report from the Interventional Cardiology Committee and the
Training Program Standards Committee of the Society for Cardiac Angiog-
raphy and Interventions. Cathet Cardiovasc Diagn 1993;30(1):1–4.
52. Report of the Ad Hoc Committee on Physician-Specific Mortality Rates for
Cardiac Surgery. Ann Thorac Surg 1993;56(5):1200–2.
53. Epstein RS, Sherwood LM. From outcomes research to disease manage-
ment: a guide for the perplexed. Ann Intern Med 1996;124(9):832–7.
54. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA,
Krumholz HM, Vogel RA. Quality of care for Medicare patients with acute
myocardial infarction. A four-state pilot study from the Cooperative Car-
diovascular Project. JAMA 1995;273(19):1509–14.
55. Ellis SG, Omoigui N, Bittl JA, Lincoff M, Wolfe MW, Howell G, Topol EJ.
Analysis and comparison of operator-specific outcomes in interventional
cardiology. From a multicenter database of 4860 quality-controlled proce-
dures. Circulation 1996;93(3):431–9.
56. Green J, Wintfeld N. Report cards on cardiac surgeons. Assessing New York
State’s approach. N Engl J Med 1995;332(18):1229–32.
57. Chassin MR, Hannan EL, DeBuono BA. Benefits and hazards of reporting
medical outcomes publicly. N Engl J Med 1996;334(6):394–8.
Task Force 4: Referral Guidelines and the Collaborative Care of
Patients With Cardiovascular Disease
W. BRUCE FYE, MD, FACC, CO-CHAIR, NORA F. GOLDSCHLAGER, MD, FACC, CO-CHAIR,
JOSEPH V. MESSER, MD, FACC, SIMEON A. RUBENSTEIN, MD, FACC
Published referral guidelines are rapidly becoming a significant
factor in the complex equation that determines the flow of
patients between primary care physicians and specialists such
as cardiologists. This task force explored several aspects of
referral guidelines, including the challenges of creating and
implementing them, their potential impact on collaborative
patient care, and their legal implications.
Ideally, referral guidelines should encourage primary care
physicians to refer appropriate patients to specialists in a
timely manner to improve short-term and long-term clinical
outcomes. They should also help prevent unnecessary refer-
rals that can increase the cost of medical care. It is evident
that managed care organizations are more likely to adopt
guidelines that restrict or delay referral, and specialists are
more likely to develop guidelines that encourage prompt
referral. Despite significant shortcomings in the commercial
referral guidelines that are available at the present time,
they are being used in many health care markets and
practice settings. The topic of this task force is timely,
because interest in creating and using referral guidelines is
increasing.
Historical Perspective
Physicians have collaborated in the care of patients since
antiquity. The Hippocratic writings, dating from about 400 B.C.,
address this important aspect of professional relations: If a
physician finds himself “in difficulties on occasion over a
patient . . . he should urge the calling in of others, in order to
learn by consultation the truth about the case. . . . For when a
diseased condition is stubborn . . . one must not be self-
confident . . . it is no mistaken idea to call in a consultant” (1).
In 1889, Baltimore physician Webster Cathell (2) encour-
aged America’s doctors to “ask for a consultation in all
important cases in which knotty problems are presented, or
where there exists any doubt as to the diagnosis . . . and in all
cases where you think either the patient’s interest, his pro-
tracted lack of improvement, or the appearance of fresh or
puzzling symptoms, or a division of responsibility demands it;
then another eye and a different mind may be of great service.”
The practice arrangements and referral patterns that have
evolved during the past century reflect a multitude of scientific,
technological, social, and economic influences. Eventually,
these forces led to the development of cardiology as a specialty
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and the transformation of general practice into family medi-
cine (3,4). Historically, most Americans have been able to
choose their personal physician and to see a specialist if they so
desired. In 1927 Chicago internist James Herrick (5) noted the
“tendency on the part of the laity to demand and secure
firsthand, i.e., over the head of the family doctor the services of
the expert, i.e., what in their view are the best services.”
Many managed care plans restrict access to specialists in an
effort to control cost, and concerns about the economic
implications of consultation and patient-initiated self-referral
are not new. Boston internist Francis Peabody (6) explained in
1930 that “the modern layman of the educated, and often of
the comparatively uneducated classes . . . has attempted to get
the best care, without regard to cost.” Because less than 10
percent of Americans had health insurance at the time, most
patients paid for the care they sought. Anticipating the
managed care paradigm, a writer in the New England Journal
of Medicine (7) complained the same year that “over-
specialization is unnecessary and costly to the public, par-
ticularly where self-diagnosis and selection of specialists is
practiced by the patient.” The challenge was to develop a
model that would encourage meaningful collaboration and
improved outcomes—and would be acceptable to patients
and their doctors.
Although the term gatekeeper was added to the medical
lexicon only recently, the concept was described in the United
States during the Great Depression, when specialization was
growing rapidly and concern about the cost of health care was
increasing. The Committee on the Costs of Medical Care (a
multidisciplinary panel of 48 medical practitioners, public
health physicians, hospital administrators, nurses, social scien-
tists, and lay persons) concluded in 1932 that “Many patients
now go directly to independent specialists without first consult-
ing a general practitioner. This practice increases the complex-
ity and the cost of medical services” (8). The committee
recommended that every American city with a population of
more than 15,000 should have one or more “medical centers”
where health care services would be delivered in a coordinated
manner. “Preventive medicine would receive special empha-
sis. . . . Within the medical center, the role of the family
practitioner would be prominent and respected. . . . Each
patient would be primarily under the charge of the family
practitioner of his choice. . . . The patient would look to his
physician for guidance and counsel on health matters and
ordinarily would receive attention from specialists only when
referred to them by his physician” (8). The committee’s report
was largely ignored, “swept aside in the rush of technological
breakthroughs, the growth of specialism, and the increasing
affluence that followed World War II,” according to health
policy analyst Anne Somers (9).
The Millis Report, published in 1966, helped set the stage
for the modern managed care movement. It summarized the
findings and recommendations of the Citizens Commission
on Graduate Medical Education, sponsored by the Ameri-
can Medical Association (AMA). The report catalyzed the
reinvention of the general practitioner as a primary care
specialist and the creation of the American Board of Family
Practice. The commission championed a new type of doctor,
the “primary physician” who would be “competent and
willing to offer comprehensive and continuing care.” This
doctor would “serve as the primary medical resource and
counsellor to an individual or a family. When a patient
needs hospitalization, the services of other medical special-
ists, or other medical or paramedical assistance, the primary
physician will see that the necessary arrangements are made,
giving such responsibility to others as is appropriate, and
retaining his own continuing and comprehensive responsi-
bility” (10).
As concern about the availability and cost of health care
increased during the late twentieth century, Congress
passed several laws designed to enhance access and con-
trol the growth of federal spending on health care. One of
these laws, the Health Maintenance Organization Act of
1973, stimulated the growth of the managed care industry
(11–13). Managed care plans have been successful in the
marketplace mainly because they promise short-term sav-
ings to employers and other purchasers of health insurance.
Today, most cardiovascular specialists in the United States
have some affiliation with one or more managed care
organizations (14).
Because controlling access to technology and specialists is
an important factor in managed care’s cost-savings equation,
more than 90 percent of health maintenance organizations
(HMOs) contract primary care physicians to serve as case
managers or gatekeepers (15). Some primary care physicians
have expressed concern about the gatekeeper model that
requires them to control access to specialists, certain diagnostic
tests, therapeutic procedures, and inpatient care. Somers (9)
explains: “The gatekeeper role, if appropriately discharged, is
obviously complex, requiring a great deal of knowledge and
many different skills.”
In many practice settings, family physicians are not the only
primary care providers: most general internists and many
internal medicine subspecialists also perform this function.
The Federated Council for Internal Medicine recently estab-
lished a high standard for general internists: “As a specialist in
the care of adults, the general internist combines the charac-
teristics of a humanist clinician, diagnostician, primary care
physician, consultant, and expert in disease prevention, health
promotion, continuing care, and the management of patients
with advanced disease” (16–18).
The Pew Health Professions Commission predicted re-
cently that primary care in the future would not be dominated
by physicians because “nurse practitioners, nurse mid-wives
and primary care physician assistants deliver care that is of a
high quality and responsive to patient needs for access and
consumer satisfaction” (19,20). It remains to be seen what
types of physicians or physician extenders managed care
organizations will prefer as primary care providers as this
health care delivery model matures (21,22).
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Referral Guidelines as a Method for Defining
the Complementary Roles of Primary Care
Physicians and Specialists
Payers and providers use guidelines, critical pathways, and
care maps to help them steer patients through the increasingly
complex world of health care delivery more efficiently. The
challenge is to prove that these new generic approaches
achieve the desired result: high quality care that is necessary
and is delivered by the appropriate provider in a timely manner
in the optimal setting at a reasonable cost. Many managed care
organizations have purchased or developed referral guidelines
to help them rationalize the use of consultants, technologies,
and therapies. Because these referral guidelines were devel-
oped mainly to reduce expenses by limiting what managed care
administrators and others have defined as unnecessary ser-
vices, they have caused concern among specialists, their pa-
tients, and organizations that view themselves as advocates for
specialists and patients (23). The American Heart Association
(AHA), a voluntary health organization, supports the mission
of the Patient Access to Specialty Care Coalition “to ensure
that prompt and direct access to medical and surgical special-
ists is available for the vast majority of the US population”
(24).
Staff at the American College of Cardiology (ACC) have
concluded that “one of the most troubling developments for
cardiovascular specialists in the evolving health care delivery
system is the deliberate attempt by managed care organiza-
tions to control and/or limit referrals for specialty care” (25). It
is understandable that many physicians and patients dislike
policies that restrict primary care to specialist referrals and
prohibit patients from seeking specialty care directly. In many
markets, the threatened loss of patient-initiated self-referrals is
problematic since family physicians refer fewer than 3 percent
of patients they see to another doctor. They consult cardiolo-
gists less often than many other specialists (Table 1) (26).
Moreover, referral rates fall if an approval process that re-
quires review by colleagues is instituted (27).
Theoretically, referral guidelines attempt to describe an
interface between primary care physicians and specialists (28).
The “first-generation” referral guidelines created in the early
1990s have approached the problem by attempting to define
the scope of practice for the primary care physician. They
specify what conditions he or she should diagnose and treat
independently and what circumstances justify referral to a
specialist. It is widely acknowledged, however, that available
referral guidelines oversimplify clinical practice and the dy-
namic and complex process of referral.
Traditionally, primary care physicians have referred their
patients to specialists to help establish a diagnosis, define
and/or provide optimal therapy, and participate in follow-up
care as needed. Several factors determine the threshold for
specialty referral, including the severity and acuity of the
illness, the patient’s (and family’s) wishes, the availability of
diagnostic procedures, access to specialists, and the primary
care physician’s degree of confidence in dealing with the
problem at hand (including interpreting various signs, symp-
toms, and laboratory tests as well as initiating and evaluating
the response to therapy). The threshold for referral therefore
depends on a variety of objective and subjective contextual
factors, most of which are not addressed in referral guidelines.
Individuals or groups seeking to create referral guidelines
face many challenges, including (but not limited to) significant
variations in the knowledge, training, and experience of the
primary care physicians who are expected to use them. It is
difficult to create a generic document that acknowledges the
uniqueness of each patient and each physician, the educational
value inherent in collaboration, and the significance of the
medical and social interaction among two doctors and a patient
that a referral triggers. Just as patients vary in their sophisti-
cation and expectations, each practice setting and community
has a culture and context that may influence the implementa-
tion and effectiveness of referral guidelines. For this reason,
any referral guidelines must be adapted to the specific regional
or local context.
Referral guidelines do not address many important aspects
of the ongoing process of collaborative care. Physicians sharing
responsibility for a patient have obligations to each other and
to their mutual patient, including timely communication of
pertinent information—from the referring physician to the
consultant and back to the referring physician. The consultant
should avoid serial referrals to other specialists without con-
currence of the primary care physician. He or she should
return the patient to the primary care physician for ongoing
management when the clinical condition warrants it.
There is no standard method for developing referral guide-
lines or assuring that they will be adopted or used appropri-
ately. Understandably, the content of referral guidelines re-
flects the opinions and interests of their creators. Robert and
Suzanne Fletcher (29), former editors of the Annals of Internal
Medicine, recommend that guidelines should be created by
“experts,” but they acknowledge the potential for conflict of
interest. “Experts in the content area—for example, subspe-
cialists in the disease in question—have much to contribute,
but they also have vested interests that may color recommen-
dations that bear on their customary thinking, prestige, and
remuneration.” Meanwhile, “economists give costs their due
Table 1. Specialties Most Frequently Consulted by Family
Physicians (in decreasing order of frequency)*
General surgery
Orthopedics
Obstetrics/gynecology
Otolaryngology
Ophthalmology
Urology
Neurology
Dermatology
Cardiology
Psychiatry
*From Rakel (26).
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but may be insensitive to quality and simply assume that the
lowest-cost care is best.”
Referral guidelines should reflect accepted medical practice
as delineated by national consensus (such as the ACC/AHA
practice guidelines on congestive heart failure and acute
myocardial infarction). Ideally, representatives of the several
interested parties should have input into their content (Table
2). Although such an inclusive approach to guideline develop-
ment is impractical, it is important to acknowledge and blend
the opinions of the main groups whose interests often define
the extremes. At all levels (national, regional, and local), the
group or committee that develops or refines referral guidelines
should include primary care physicians and cardiovascular
specialists in addition to managed care administrators.
Reimbursement strategies such as capitation can influence
the behavior of physicians and their attitudes toward practice
and referral guidelines (30). Various types of financial and
nonfinancial incentives may encourage or discourage referrals.
Most doctors practicing in capitated groups have voluntarily
adopted utilization management policies and procedures that
many physicians practicing in a fee-for-service environment
perceive as intrusive. In a recent study of 94 physician groups
that were part of a large network HMO in California, Kerr et
al. (31) found that they all used gatekeepers and required
preauthorization for certain referrals or tests. The authors
concluded that “capitation at the group level has influenced
physicians to devise their own management systems to contain
costs.” They predicted that “as managed care expands, physi-
cians in other states will probably face the challenge of
capitation and will respond with utilization management strat-
egies” (31).
Patients have a right to know what economic and noneco-
nomic incentives their health plans use to influence participat-
ing physicians to make certain choices with respect to resource
utilization such as specialty referral (32,33). David Orentlicher,
director of the AMA’s Division of Medical Ethics, emphasizes
the undesirable effects of economic and noneconomic incen-
tives designed to discourage primary care physicians from
making referrals. Under certain circumstances, these doctors
“might assume responsibility for care that should be referred
to more expert and more expensive specialists” (34–36).
Marcia Angell, executive editor of the New England Journal
of Medicine, explains that some HMOs “withhold a portion of
doctors’ salaries if they refer patients to specialists too often or
use too many tests and procedures. These doctors become
‘agents’ for the HMO and have a direct incentive to undertreat
their patients, just as in the fee-for-service system they have an
incentive to overtreat them” (37,38). Because the traditional
fee-for-service reimbursement model is predicated on paying
physicians for each service they provide, it can encourage them
to deliver more care and use more resources than might be
necessary. The challenge in creating and implementing referral
guidelines is to find the proper balance between altruism and
self-interest, both individual and corporate (39,40). Ideally,
from the physician’s perspective, the referral process should be
financially neutral and free of other incentives. Referral guide-
lines should not encourage inappropriate referrals to a col-
league at financial risk or restrict referrals by a physician whose
patient would benefit from them.
The Creation of Referral Guidelines:
Two Examples
Milliman & Robertson, Inc. (M & R) an actuarial and
health care consulting firm founded in 1947, has been the main
source of referral guidelines in the United States. This Seattle-
based firm employed approximately two dozen physicians and
nurses to develop practice guidelines in recent years. They
proposed the 24-hour length-of-stay for normal childbirth that
caused concern recently among women, potential parents,
health care providers, and others. A public outcry led to
legislation that requires insurers to pay for at least two days of
hospitalization. In this context, medical writer Farah Kostreski
(41) predicted that “in 1996 the lightening-rod issue is ex-
pected to be the company’s referral guidelines, especially those
for cardiology.”
Richard Doyle, M & R’s senior health care management
consultant, has played a major role in developing their guide-
lines since 1988. He has had a longstanding interest in resource
utilization and became convinced that “we needed to stimulate
more efficient care.” M & R did so by setting ambitious targets,
termed “best practice,” with respect to the need for hospital
admission, the duration of hospitalization, and the indications
for specialty referral (Doyle RC, Fye WB. Personal communi-
cation, 1996).
The M & R referral guidelines are very succinct—they do
not include references to support their recommendations.
Most physicians view them as very restrictive. One example
from the cardiology guidelines illustrates the point: “Primary
care physicians should treat angina medically with risk factor/
lifestyle modification and with nitrates, beta blockers, calcium
channel blockers, and other medications as appropriate. Con-
sult for angina occurring despite maximal medical treatment
with maximally tolerated doses of nitrates, beta blockers, and
calcium channel blockers” (42,43).
The M & R referral guidelines reflect the firm’s belief that
primary care physicians should assume major responsibility for
managing most of their patients’ health care needs. Although
Table 2. Parties Interested in the Content of Referral Guidelines
Patients
Primary care physicians
Specialists
Families
Payers (e.g., employers)
Managed care administrators
Clinic and hospital administrators
Nonphysician medical personnel
Government officials
Medical malpractice lawyers
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their guidelines acknowledge that “the skills and interests of
physicians with responsibility for primary care are variable,”
the “protocols assume that primary care physicians will provide
successful cognitive care for most patients.” They also state
that “those primary care physicians who achieve optimal health
care status for their patients by decision-making of moderate
and high complexity, as well as appropriate use of diagnostic
and performance of some therapeutic procedures, are more
valuable than those who do not” (43). Doyle explains that they
are “more valuable because you are not going to need to use
the cognitive or procedural specialists as often” (Doyle RC,
Fye WB. Personal communication, 1996).
Although their guidelines are designed to discourage refer-
rals, M & R explain that “it must be understood that undiag-
nosed or intractable problems, in which the patient’s optimal
health status has not been achieved or restored, should have
consideration by another physician” (44). Many primary care
physicians do not embrace the doctrine of late referral. There
are social and scientific reasons for this. Academic family
physician Robert Rakel (26) advises that “an early consultation
is much less likely to damage patient confidence than a delayed
one. The confident and secure physician who considers patient
welfare to be of the utmost importance is not threatened and
freely utilizes consultants at the appropriate, sometimes early,
stage of a problem, before it has progressed to serious propor-
tions that are more difficult to manage.”
In response to M & R’s referral guidelines, the California
Chapter of the ACC published “Guidelines for Referral to a
Cardiovascular Specialist” in July 1995 (45). The task force
that developed them included fourteen college fellows: cardi-
ologists (practitioners and academics) active in general cardi-
ology and/or subspecialties such as echocardiography or elec-
trophysiology. The California cardiologists, like many of the
nation’s heart specialists (and other specialists), felt that
M & R’s restrictive referral guidelines threatened their tradi-
tional role in the patient care and might result in delayed
diagnosis, unnecessary testing, and suboptimal outcomes (45).
Writing on behalf of the North American Society of Pacing
and Electrophysiology (NASPE), electrophysiologists David
Benditt and Sanjeev Saksena expressed concern about the
implications of restrictive referral guidelines (46). They and
the California ACC task force argue that optimal referral
guidelines should encourage effective collaboration between
primary care physicians and specialists. “The consultation
process,” Rakel (26) notes, “works best when two physicians
work together as colleagues to solve a difficult patient problem.
The process is usually a learning opportunity for the referring
physician.”
The California ACC guidelines address seven clinical cate-
gories: hyperlipidemia, hypertension, congestive heart failure,
arrhythmias, chest discomfort, cardiac murmurs, and children
with suspected cardiovascular disease. They are more permis-
sive than the M & R guidelines with respect to the indications
for referral. But the mere existence of referral guidelines does
not imply their acceptance. The California guidelines were sent
to every HMO and insurance company in the state, but it
appears that few organizations have used them to this point
(Goldschlager N, Fye WB. Personal communication, 1996).
Nine months after the California ACC chapter published
their guidelines, Nora Goldschlager reported, “Although the
guidelines have enjoyed wide popularity among specialists,
primary care physicians have endorsed neither the concept nor
the substance of the guidelines, nor have payers recognized the
longer term cost reduction and medical prudence of the
‘referral guidelines’ when weighed against the (likely higher)
up front costs.” Susan Hogeland, Executive Director of the
California Academy of Family Practice, explained that family
physicians who reviewed the California ACC guidelines
thought they were too liberal with respect to the indications for
referral (41).
It is apparent that the creation and dissemination of referral
guidelines does not guarantee that they will be endorsed,
formally adopted, or followed. Several factors determine how
guidelines are used in a specific context, including their
content, their relevance to local practice, and their economic
implications.
Outcomes Research in
Cardiovascular Disease
One of the most problematic aspects of referral guidelines
is their subjectivity. Increasingly, medical decisions are being
based on various types of objective information, so-called
evidence-based medicine. This trend reflects advances in re-
search design, better statistical methods, and the impact of
computers on science and medicine, but it is part of a larger
cultural phenomenon. As consumerism increased in the
United States in recent decades, patients and payers began to
expect more from their doctors and hospitals. Attention is now
being focused on managed care organizations—especially
their policies and profits. Various interested parties are now
asking them to demonstrate that their policies (including those
that restrict access to specialty care) do not adversely affect
outcomes.
Most would agree that it is intuitive that cardiologists,
because of their additional focused training and experience,
know more about the pathophysiology, diagnosis, and treat-
ment of heart disease than primary care physicians. But in this
era of managed care, specialists (and their professional soci-
eties) are beginning to realize that they need to prove that their
unique expertise and technical skills improve outcomes and
add value (47). If they cannot, their role in America’s health
care delivery system will decrease even more than it is pro-
jected to under managed care.
Many controlled clinical trials have shown that specific
cardiac treatments, such as early reperfusion and adjunctive
pharmacologic therapy for acute myocardial infarction, pro-
long life and improve functional status (48). Studies evaluating
interspecialty differences in the short-term outcomes of pa-
tients with acute cardiac disease are just beginning to appear in
the literature, however. Some investigators are focusing on
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interspecialty differences in clinical outcomes, while others are
studying the cost of the evaluation and management process of
patients with known or suspected heart disease. The American
Society of Internal Medicine recently challenged managed care
organizations to “evaluate the cost of subspecialist and primary
care physicians by using severity-adjusted economic profiles
and other measures of physician performance, rather than
arbitrarily limiting subspecialists’ scope of practice because of
cost-effectiveness concerns” (49).
Schreiber et al. (50) studied the consequences of whether a
general internist or a cardiologist directed the care of patients
hospitalized with unstable angina. They found that those
treated by internists were less likely to receive effective medical
therapy or revascularization procedures and experienced a
trend to poorer outcome. Schreiber et al. (50) concluded that
their study “does not support a positive gatekeeper role for
generalists in the treatment of unstable angina.” Similarly,
Ayanian et al. (51) found that “internists and family practitio-
ners are less certain about key advances in the treatment of
myocardial infarction than are cardiologists.”
In a 1993 study of 39,256 cases of acute myocardial infarc-
tion, the Pennsylvania Health Care Cost Containment Council
(52) found that “cardiologists had fewer patient deaths than
expected and shorter lengths of stay than expected across all
hospitals. Patients treated by physicians specializing in internal
medicine stayed in the hospital longer than expected across all
hospitals. Family medicine physicians practicing in hospitals
without advanced cardiac services had more patient deaths
than expected. Physicians practicing internal medicine in hos-
pitals with advanced cardiac services had more deaths than
expected.”
Some research suggests that earlier referral to a cardiologist
can reduce the overall cost of evaluating and managing a
person with known or suspected heart disease. In a study of the
appropriateness of radionuclide exercise stress testing, Stein
et al. (53) concluded that while both cardiologists and
noncardiologists overutilized these tests, noncardiologists
were more likely to order tests that were not indicated.
Referral to a cardiologist before ordering the test resulted
in cost savings. (53). In a study of patients with a positive
exercise stress test, Borowsky et al. (54) found that “the
present study cohort was more likely to undergo medically
necessary coronary angiography when a cardiologist was the
regular source of care.”
Cardiologist and health policy analyst Tom Lee (55) con-
cludes that “common sense and recent research support the
expectation that patients with serious cardiovascular syn-
dromes benefit from subspecialty care.” He suggests that “the
real goal of an effective provider organization is not to keep
patients away from subspecialists; rather, it is to keep the low
risk patient away from inpatient nursing care and procedures
from which that patient is not likely to benefit. This goal is
consistent with a definition of quality of care that matches
patients’ needs with resources.” Lee (55) advocates “strategies
that allow rapid access to subspecialists for patients who are
likely to benefit from subspecialty care and procedures.”
Most persons with stable chronic heart disease are not
followed regularly by cardiologists, and it is unlikely that this
will change. The writing group of Task Force 4 of the ACC’s
25th Bethesda Conference (56) concluded that “it is in soci-
ety’s best interest to have generalists give as much cardiologic
care as they can give safely and effectively.” Lee (55) agrees
that “patients who are not likely to benefit from a subspecialist
should receive their care from a primary care physician.” The
challenge is to decide just when an individual patient might
benefit from seeing a cardiologist.
Managed care organizations are pragmatic and their guide-
lines reflect this philosophy. They have chosen to implement a
spectrum of utilization policies in the absence of clinical
outcome data. Although objective and reproducible data that
demonstrate benefit at a reasonable cost should be the stan-
dard when new therapies or care plans are introduced, this is
idealistic. After reviewing the various ways that doctors choose
diagnostic and treatment strategies, physician and health pol-
icy analyst Clement McDonald (57) concluded “there will
never be enough randomized trials or epidemiologic studies to
guide every clinical decision.”
Peter Dans (58), deputy editor of the Annals of Internal
Medicine advises that “guidelines must be based on sound
evidence, supplemented where necessary by truly expert
opinion. Except where supporting data are incontroverti-
ble, guidelines should be regarded as works in progress.”
Organizations such as the ACC and the AHA and the
federal government should encourage and fund research
that compares patterns of resource utilization and clinical
outcomes of heart patients managed by cardiologists and
noncardiologists.
Medical Training and the Collaborative Care
of Patients With Cardiovascular Disease
Board-certified cardiovascular specialists have extensive
focused training that distinguishes them from board-certified
general internists and family physicians. The American Board
of Internal Medicine (ABIM) (59) “defines the certifiable
cardiologist at the successful completion of required training
as being competent to provide comprehensive, specialized care
based on a high standard of demonstrated component skills.”
Referring to clinical judgment, medical knowledge, clinical
skills, and other critical components of high quality cardiovas-
cular care, the ABIM believes that the skills of the certifiable
cardiologist “should clearly exceed those demonstrated by the
certified internist” (59).
The content of cardiology fellowship programs has ex-
panded dramatically in the past two decades. Moreover, the
training process has become more rigorous, with higher expec-
tations for both trainees and faculty (60). The ABIM requires
a minimum of three years of cardiology fellowship training
beyond a residency in general internal medicine before they
will admit a candidate to their certification examination. A
fourth year of specialized cardiology training is required to
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take the certification examination for added qualifications in
clinical cardiac electrophysiology.
Although primary care physicians receive much less training
than cardiologists in the area of cardiovascular disease, they
are being asked or required by managed care plans to play a
more active role in the diagnosis and management of condi-
tions that have traditionally been in the realm of specialists.
For this approach to succeed in patients with heart disease, the
primary care physician must have a cognitive and experiential
knowledge base that permits him or her to accurately diagnose
and appropriately treat common cardiac disorders.
Medical schools and internal medicine and family practice
residency training programs provide a broad outline of spe-
cialty core knowledge, but there is no consistent approach with
respect to who should be responsible for imparting this infor-
mation to students and residents (61). Cardiologists should be
actively involved in the educational process as it pertains to
cardiovascular disease. The cardiovascular specialist, by virtue
of his or her advanced training and focused experience, is
usually the best person to instruct students and trainees in how
to 1) obtain a relevant history; 2) perform a thorough cardio-
vascular examination; 3) choose the most cost-effective diag-
nostic tests; and 4) define the optimal treatment strategy
(53,54,62,63).
Throughout medical training, clinical teaching at the bed-
side or in the outpatient setting must supplement classroom
exercises to optimize understanding of the pathophysiology,
diagnosis, and management of cardiovascular disease. Expo-
sure to inpatients and outpatients is equally important. Spe-
cialists who have the opportunity to participate in the training
and supervision of residents in family medicine and general
internal medicine are the ones best able to assess the ability of
these primary care physicians to evaluate and manage patients
with cardiovascular disease.
The fund of knowledge and clinical expertise with respect to
the evaluation and management of patients with cardiovascu-
lar disease attained by the end of the internal medical resi-
dency is highly variable(51,64,65). Because primary care phy-
sicians do not receive adequate training to interpret advanced
cardiac diagnostic tests, such as echocardiograms and nuclear
imaging studies, they should not be expected to do so in
practice. Many primary care physicians interpret electrocardio-
grams and monitor and interpret standard treadmill exercise
tests. They should be able to demonstrate competence in
providing these services, however. The ACP/ACC/AHA Clin-
ical Competency Statements provide guidance for many such
procdures (see Task Force 3). It is inadvisable and unethical to
expect or to permit individuals to practice beyond the scope of
their training and experience.
Legal Implications of Referral Guidelines
The legal implications of referral guidelines are beginning
to receive attention. Only a small percentage of medical
malpractice lawsuits result in a jury verdict, and a recent
RAND study (66) found that plaintiffs won only 33 percent of
such suits. Failure to refer a patient to a specialist in a timely
manner, however, has resulted in significant malpractice
awards. Three of eleven recent verdicts against managed care
organizations reviewed by the Medical Insurance Exchange of
California involved failure to refer to specialists, and the
awards ranged from $500,000 to $2,952,000 (67).
Perverse economic incentives and the increasing use of
restrictive referral guidelines place primary care physicians in
the untenable situation of having to choose between patient
advocacy and financial reward. Juries are unsympathetic to this
dilemma, and often recommend large awards that include
substantial punitive damages. In one well-publicized case
(Ching v. Simi Valley Family Practice Inc. [68]), death was
attributed to delayed referral to a gastroenterologist. The
plaintiff’s attorney argued successfully that economic incen-
tives played a significant role in the primary care physician’s
decision to delay referral to a gastroenterologist.
As referral guidelines are used more widely in managed
care, they will be drawn inevitably into litigation as a subset of
managed care policies. Recognizing the growing popularity of
various types of clinical practice guidelines, the National
Health Lawyers Association (69) has addressed a wide range of
legal issues related to their development and implementation.
In addition to discussing legal issues related to the creation,
validation, and dissemination of guidelines, they report on the
relationship of guidelines to standards of care, the physician’s
fiduciary responsibility, and quality issues.
Although referral guidelines are becoming an integral
component of some managed care contracts, physicians cannot
assume that they will insulate them from liability. Document-
ing patient advocacy is the physician’s best defense against
managed care liability. Primary care physicians should appre-
ciate the concept of vicarious liability. If the approved panel of
specialists available to a primary care physician is too restric-
tive, the primary care physician may be held vicariously liable
for the inadequate care provided by the specialist (70).
The plaintiff and defense attorneys who attended the 1994
National Health Lawyers Association Colloquium agreed that
although clinical practice guidelines would not have a major
impact on malpractice actions, they would be used as evidence
to define the applicable standard of care (69). Increasingly,
plaintiffs are using guidelines to screen for potential liability
cases. In the past, guidelines have been of greater value to
plaintiffs than to defendants (71). This situation may change as
a result of the Maine Medical Liability Demonstration Project,
however, in which guidelines can be used only as an affirmative
defense in malpractice suits. Some states now require managed
care plans to disclose their referral guidelines to subscribers
(68).
The Employment Retirement Income Security Act of 1974
(ERISA) increases the legal ambiguity of clinical practice
guidelines, including referral guidelines. This Act was created
to exempt self-insured companies from state regulations, in-
cluding state malpractice statutes. More than 60 percent of
Americans with health insurance participate in such self-
insured plans. Plaintiffs suing self-insured medical care orga-
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nizations are limited to contractual remedies that often pro-
vide insufficient compensation to an individual for harm that
resulted from restricting care or professional negligence. Since
physicians are always liable for negligence, they are attractive
targets when patients suffer adverse results from a course of
action dictated by the plan’s utilization review and benefits
policies.
The shifting of liability from health care organizations to
physicians as a result of ERISA “Preemption” has been
challenged recently. The concept of vicarious liability has been
used against managed care organizations when plan adminis-
trators supervise physician behavior too closely. Furthermore,
the recent precedent-setting Dukes v. U.S. Health Care Inc.
case (72) suggests that state courts will be allowed to apply
theories of liability to health plans in suits that involve tort
damages in addition to contract damages now available under
ERISA. AMA attorney Carol O’Brien thinks this is a “positive
trend to the extent that HMOs that are supervising and actively
involved in medical treatment can be held liable” (73). The
application of state regulations in such cases underscores the
increasing importance of local guideline implementation.
Many physicians, especially primary care physicians who are
expected to serve as gatekeepers, feel threatened by the
liability aspects of managed care. While the courts assume that
physicians have discretion, and therefore liability, medical care
organizations have undermined that discretion with gag
clauses, practice parameters, and guidelines that restrict access
of patients to specialists. The legal implications of guidelines
may actually enhance the collaborative care of patients with
cardiovascular disease. Concern about liability may result in
more realistic referral guidelines that insure timely access to
specialty care and acknowledge the expanding responsibilities
of primary care physicians.
Recommendations
Recommendation 1. Collaboration between primary care
physicians and cardiovascular specialists should be encour-
aged. A bidirectional process that is enhanced by effective
communication and collaborative care has traditionally been
focused on diagnostic procedures, risk stratification, and treat-
ment recommendations or procedures. Optimal collaborative
care must go beyond these key elements, however, and should
include shared responsibility for education, risk factor modifi-
cation, and appropriate follow-up.
Recommendation 2. A joint ACC/AHA committee should
develop referral guidelines as a template for the collaborative
care of patients with known or suspected cardiovascular dis-
ease. These referral guidelines should be based on current
clinical practice guidelines. The standard ACC/AHA classifi-
cation system (i.e., class I, II, or III indications) should be
adapted for use with the referral guidelines. An ACC state
chapter or a local committee could then adapt the national
referral guidelines to a specific regional or local context.
Recommendation 3. At all levels (national, regional, and
local), the committees that develop or refine referral guide-
lines should include primary care physicians and cardiovascu-
lar specialists in addition to managed care administrators.
Ideally, other interested parties should be represented, espe-
cially at the local level (see Table 2 for examples of potential
participants).
Recommendation 4. Commercial referral guidelines that
are currently available should be used with caution because
they tend to oversimplify clinical situations, and their primary
intent is to limit resource utilization in a population of enrolled
persons rather than to ensure the best clinical outcome in an
individual patient.
Recommendation 5. Organizations (e.g., the ACC and
AHA) and the federal government should encourage and fund
research that compares resource utilization and clinical out-
comes of patients with cardiovascular disease managed by
cardiologists and other providers (e.g., primary care physicians).
Recommendation 6. Guidelines must not be viewed as
absolute. Managed care organizations should permit specialty
referral despite their guidelines in situations where the primary
care physician and specialist agree that it is in the best interest
of the patient.
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The development of clinical practice guidelines for most
cardiac syndromes requires knowledge of the safety, efficacy,
and cost effectiveness of cardiovascular technologies. Because
new technology normally evolves through multiple iterations, it
typically undergoes evaluation before and after it is made
commercially available. In the 1990s there has been increasing
disagreement about how technology approval and assessment
should be structured to best meet society’s needs. This Task
Force describes the history of technology assessment, the
current process of pre- and postmarket assessments, and the
markedly different perspectives of the users. After consider-
ation of the current limitations perceived by the users, the Task
Force proposes a major change in the system used for tech-
nology assessment in the United States.
History of the Technology Approval Process
The first law to protect the public from the unrestricted sale
of potentially unsafe drugs was passed by Congress in 1902. In
contrast, medical devices were marketed without review by the
U.S. Food and Drug Administration (FDA). As medical
devices became increasingly complex in the post-World War II
period, the marketing of sophisticated medical devices without
adequate testing became more frequent. Public disclosure of
the shortcomings and failures of medical devices, such as heart
valves, pacemakers, intrauterine devices and intraocular
lenses, led the government to reconsider this unsupervised
marketing of medical devices during the late 1960s.
Following President Nixon’s October 1969 consumer mes-
sage, the Secretary of Health, Education, and Welfare (HEW)
established a Study Group on Medical Devices, chaired by Dr.
Theodore Cooper, then Director of the National Heart and
Lung Institute. The Cooper Committee considered and re-
jected the possibility of applying regulatory drug law to new
medical devices. Instead, the Committee recommended two
immediate steps: an inventory of all medical devices already on
the market, and an initial classification of the risk associated
with those devices. The Committee proposed that the degree
of regulation by the FDA would then be based on the potential
risk and benefit to the patient. In very ill patients with limited
options, the degree of regulation could be less demanding.
Conversely, the more hazardous a device, the more rigorous
the regulation. This philosophy differed from the regulation of
new drugs, where standards of safety and effectiveness were
applied uniformly. The recommendations entered legislation
as the Medical Device Amendments of 1976.
The Current Regulatory Process
Figure 1 outlines the current regulatory process for devices.
First, the device is classified as a Pre-Amendment device (or
old device) on the market prior to the 1976 legislation, or a
Post-Amendment device (or new device). Next, the device is
classified by its degree of risk. Class I devices are only required
to satisfy general controls which include registration and good
manufacturing practice (GMP). Examples of Class I devices
include tongue depressors and stethoscopes. Class II devices
are subject to both general controls and performance stan-
dards. Examples include infusion tubing, monitoring equip-
ment, and surgical masks. Finally, Class III includes devices
that carry significant risk as well as potential benefit. Such
devices include heart valves and stents. Class III devices cannot
be marketed until the manufacturer demonstrates their safety
and effectiveness to the FDA.
The evaluation and approval for marketing of new devices
is generally by one of two avenues. For Class I and II devices,
in the Premarket Notification, commonly referred to as a
510(k), the manufacturer demonstrates a substantial equiva-
lence to a device with an existing 510(k) or a device that was
marketed prior to 1976. The device must have the same
intended use, same technological characteristics, and be at
least as safe and effective as the one to which it is compared.
Although the FDA may require additional clinical or labora-
tory studies, clinical data have not been included for 95%
devices marketed via this path. The vast majority (90%) of
510(k) submissions are approved.
The other route to market is via the premarket approval
(PMA). This mechanism is used for Class III devices or for
technology for which there is no existing equivalent. Demon-
stration of safety and effectiveness of PMA devices typically
involves extensive safety and efficacy testing, including clinical
trials.
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Clinical studies are carried out under an FDA investiga-
tional device exemption (IDE). As the name suggests, the IDE
exempts the sponsor from commercial restrictions on unap-
proved significant risk devices in the United States. An IDE
application includes laboratory and animal data, a clinical
study design, hypotheses, procedure protocol, proposed statis-
tical analyses, case report forms, informed consent materials,
and proposed device labeling.
The IDEs, PMAs and 510(k)s fall under the authority of the
Office of Device Evaluation, a section of the FDA’s Center for
Devices and Radiological Health (CDRH). This office received
16,978 submissions in 1995 (Table 1).
Supplements are requests for changes, either in the ap-
proved device or in the labeling, packaging, or manufacturing
processes. For 510(k)s a supplement is required for changes in
device design or manufacturing processes which could signifi-
cantly affect safety and effectiveness or for a change in the
indications for use. PMAs require a supplemental application
for changes in device design or in manufacturing process which
may affect safety and effectiveness, change in manufacturing
facility, or change in indications for use, or change in labeling
that may affect safety and effectiveness.
The Process of New Technology Development
The development of new devices can be divided into four
principal phases: preclinical development, early clinical devel-
opment, trials to support marketing, and postmarketing trials.
Preclinical development includes optimizing bioengineering de-
sign and preliminary bench and animal testing. As a general
Figure 1. Market access routes for medical devices. FDA 5 Food and
Drug Administration; GMP 5 good manufacturing practice; PMA 5
premarket approval.
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rule, the medical device industry has had little trouble meeting
preclinical FDA requirements. Early clinical development un-
der an IDE usually involves a pilot trial, after safety issues have
been worked out on the bench and in animals. They are
performed for the benefit of the developer or manufacturer.
The pilot trial provides investigators with initial device expe-
rience, establishes an operator learning curve, permits an
initial assessment of device design, addresses specific safety
concerns, helps define the clinical protocol, estimates the
potential therapeutic effect to permit calculation of a realistic
sample size needed for a market entry trial, and focuses
potential claims for the new device. Market entry trials in
cardiology typically require a well defined research protocol,
with specific inclusion/exclusion criteria, sample size estimates
and defined endpoints. These trials involve multiple centers,
and either data registries or randomization. The results of the
trial are frequently reviewed by the FDA Advisory Panel. Post-
marketing trials are conducted most commonly outside the
FDA agency, although from time to time, the FDA makes
changes in labeling based on such data. These trials typically
involve analysis of technology performance in subgroups of
patients who were not specifically identified in the premarket
trials. The published data from these postmarket trials are
used by professional organizations such as the American
College of Cardiology (ACC) for ongoing technology assess-
ment in clinical practice. Postmarketing surveillance studies
are also required by the FDA for all long-term implants, such
as pacemaker leads, implantable cardioverter-defibrillators,
and heart valves.
The Role of the FDA Advisory Panel in
Device Approval and Assessment
The FDA Advisory Panel is a standing committee of experts
representing the scientific community, which reviews selected
PMA applications. In recent years, the Panel has increasingly
taken the position that it needs randomized trial data to
analyze the safety and efficacy of new devices. The precedent
for this action comes from drug approvals, in which virtually all
new medications are subjected to two placebo-controlled trials
prior to FDA approval.
Prior to 1990, the FDA CDRH analyzed safety and efficacy
by comparing a submitted data registry to historical controls.
The precedent for more stringent analysis was established by
experience with directional atherectomy. Although directional
coronary atherectomy was approved on the basis of registry
data analysis in 1990, a large-scale, multicenter randomized
trial comparing this technique with balloon angioplasty was
initiated in 1991 after device approval. Completed in 1992 (1),
the trial raised safety issues about directional atherectomy
which were not noted by comparison of prior registry data to
historical controls, included doubling of the rate of non-Q
wave myocardial infarction, compared with balloon angioplasty
(1,2). The feasibility of performing randomized trials prior to
new device approval was then illustrated by two multicenter
trials of the Palmaz-Schatz coronary stent, conducted in the
United States and Europe, which led to FDA approval (3,4).
Thus, methods typically used for postmarket assessment in the
scientific community were brought to premarket assessment by
the regulatory agency. Collection of multicenter randomized
clinical trial data prior to commercialization represented a
major precedent in the device approval process.
Issues in Technology Approval
and Assessment
There are a number of issues in technology approval and
assessment that were identified by the Task Force (Table 2).
The Long Duration of the Internal Review Prior to
FDA Approval
The duration of the preclinical phase (ending with IDE
approval) depends on the complexity and maturity of the
device. The time required for IDE review is relatively predict-
able. Under the Federal Food, Drug, and Cosmetic Act and
FDA regulations, the agency has 30 calendar days from the
date of receipt of the application to approve or disapprove an
IDE submission. Over the last few years, the FDA has initiated
a number of policy and procedure changes designed to im-
prove the timeliness of device approvals. The average FDA
review time for original IDEs was 29 days in both fiscal year
1994 and 1995, whereas the percentage of IDEs approved on
the first review cycle increased from 30% in fiscal year 1994 to
57% in fiscal year 1995.
During the preapproval phase (under an IDE, and ending
with PMA approval), the sponsor must develop and certify the
manufacturing facility, complete the clinical trial and develop
and package the necessary evidence of safety and effectiveness
(file the 510(k) or PMA). The regulations permit the agency 90
Table 1. 1995 Submissions to FDA Office of Device Evaluation
PMAs 39 originals 499 supplements
IDEs 214 originals 210 amendments
510(k)s 6,056 originals 4,522 supplements
Total 6,309 5,231
FDA 5 Food and Drug Administration; IDEs 5 investigational device
exemptions. PMAs 5 premarket approvals.
Table 2. Current Problems in Technology Assessment
Long delays in FDA approval of new technology
Panel-mandated randomized trials that delay marketing
Increased cost of new technology development
Transfer of U.S. research money to Europe
Premarket trials not relevant to clinical practice
Limited availability of new technology for patients
Off-label use of technology by physicians
Payer uncertainty about reimbursement for non–FDA-approved devices
Little meaningful input from professional societies
FDA 5 Food and Drug Administration.
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days to complete the 510(k) review or 180 days to complete the
PMA review and reach a decision. The agency may elect to
present the information to the FDA Advisory Panel for
independent assessment of safety and effectiveness. After
obtaining the panel’s recommendations, the FDA is required
to approve the PMA, reject it, or request additional informa-
tion. The average FDA review time for original PMAs was 276
and 374 days in fiscal years 1995 and 1994 respectively. The
non-FDA component of review time, the time period when the
document was being revised by the submitter, averaged 80 days
during this time period.
The average total review time for 510(k) applications
decreased from 216 days in fiscal year 1994 to 178 days in fiscal
year 1995. Average FDA review times for 510(k) and PMA
originals, amendments, and supplements from fiscal year 1988
to 1995 are shown graphically in Figure 2. Recent initiatives
taken by the agency are expected to continue to improve or
stabilize review times for an increasing volume of increasingly
complex medical devices.
Delays Caused by Randomized Controlled Trials
A second major limitation of the current technology assess-
ment process is the time required to collect data required by
the randomized trials that are mandated prior to device
approval. Although the recent emphasis on premarket ran-
domized trials evolved from successful application of this
strategy for PMA of drugs, there are crucial distinctions
between drugs and devices, which were made clear in the
original Cooper Commission Report (5) (Table 3):
As a consequence, assessment methods that work well for
drugs are not very effective for dealing with rapidly changing
technologies. In addition to being insensitive to the iterative
nature of new device development, randomized trials do not
effectively capture the typical evolution of user skills and
accessory improvements. While randomized trial data can be
extremely helpful in setting the boundaries of efficacy and
safety, they are time consuming and expensive, costing several
thousand dollars per patient. New technologies are typically
first tested at a limited number of hospitals with considerable
experience, making transferability to broad clinical practice
questionable. Finally, to maximize the probability of approval,
manufacturers design trials using the lowest risk patient sub-
sets, knowing that “off-label” use after FDA approval will lead
to much broader application in more complicated patient
subsets in whom device safety and efficacy has never been
demonstrated.
With these merits and disadvantages of randomized trials,
their appropriate timing represents a key issue. Trials before
FDA approval may be completed before the technology has
matured, and before the learning curve of physicians has
plateaued. Furthermore, the duration of a randomized trial
substantially delays the FDA approval process. Without com-
mercial revenue small companies cannot defray the cost of the
trial. On the other hand, by deferring a randomized trial until
after FDA approval, the potentially most accurate data about
a new technology are not made available to the FDA Advisory
Panel. These data may reveal a safety problem or lack of
efficacy not evident in registry data. Performing a trial after
FDA approval, however, allows for more sites and physicians
to participate, a broader more relevant spectrum of patient
subsets, more rapid completion of the trial, and an improved
ability for extrapolating the data. To deal with these idiosyn-
crasies of device technology, PMA and postmarket assessment
need to be viewed as a continuum (i.e., an effective system
needs to be dynamic, not static).
Limited Availability of Effective Devices for
Patient Care
The consequences of the delay in new device approval is
limited availability of new technology, and transfer of research
and manufacturing dollars to Europe. The problem is illus-
trated by intracoronary stents, which improve early and late
clinical outcomes in patients undergoing percutaneous revas-
cularization for the treatment of coronary artery disease. More
than 15 stents have been approved for clinical use in Europe,
while in the United States the only 2 currently available stents
were designed approximately 10 years ago and have not
changed since that time. Both of these stents have important
limitations. These include lack of radio-opacity which makes
precise placement difficult, inflexible delivery systems which
Table 3. Differences Between Drug and Device Assessment
Factor Drug Device
Influence of physician technique on result Low High
Rate of technical change Low High
Ability to evaluate performance attributes in vitro Low High
Ability to visualize performance during and after use Low High
Effect of environment on performance Low High
Financial and personnel resources of developer Large Limited
Figure 2. Average Food and Drug Administration review times. FY 5
fiscal year; IDE 5 investigational device exemption; PMA 5 premar-
ket approval; Supp. 5 supplements.
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limits their use to selected lesions, and the need for multiple
balloons—one for predilation, one for stent deployment, and
one for high pressure postdeployment inflation. In countries
that have access to newer stent designs, these two older devices
are rarely used. The newer stents are more flexible, and are
mounted on high pressure balloons that obviate the need for
use of separate balloons for deployment and high pressure
dilation. Other stents are designed specifically for long lesions,
for those with side branches, and for vein graft disease. New
stents are coated to minimize subacute vessel closure. Until
these newer stents are approved in the United States, selected
patients will either not be able to benefit from stent application
or will have suboptimal results, including the need for urgent
coronary bypass surgery.
Another example involves pacemakers, cardioverters, and
defibrillators. Models currently available in the United States
have significant limitations in terms of flexibility, size, and
programmability compared to versions available in Europe. In
the past five years, smaller devices with less morbidity, and
defibrillators requiring less energy have been used in Europe
more than a year prior to their availability in the United States.
Therefore both physicians and patients have been denied
access to devices that may have reduced adverse outcomes.
Conflict of Interest Among Physician-Inventors
and Developers
Cardiologists with a significant financial interest now often
play a key role in both the development and clinical trials of
new technology. The increase in technology development is
significant. In 1980 about 30 universities were engaged actively
in technology transfer; at present about 200 are. In the period
1974–1984, 84 universities received just under 3,000 patents;
now, about half that many patents are granted to universities
each year (6). In 1986, U.S. universities reported aggregate
licensing income of $30 million; in 1994 U.S. universities
reported aggregate licensing income of $265 million (6,7).
Since October 1, 1995, the federal government has made
institutions and investigators applying for National Institutes
of Health (NIH) and National Science Foundation (NSF)
grants or cooperative agreements subject to federal conflict of
interest regulations (8). Since both new technology develop-
ment and clinical trials are often supported by such funds, this
new mandate is highly relevant to technology assessment.
Institutions are required to define, disclose and manage con-
flicts of interest, including significant financial interests. Poten-
tial financial interest is defined as anything of monetary value,
including but not limited to, salary, consulting fees or hono-
raria, equity, and intellectual property rights (e.g., patents,
copyrights and royalties from such rights) (8). The regulations
cover the manner in which data are collected, analyzed and
interpreted; the hiring and supervision of staff; the procure-
ment of materials; the sharing of research results; the choice of
protocol; and the use of statistical methods. Neither the NSF,
NIH nor other governmental agencies currently require sub-
mission of the disclosed material. Rather, the university must
advise these agencies that any conflicts are being appropriately
managed. Nonetheless, an investigation by such government
agency may require disclosure. The range of strategies which
may be required include 1) disclosure only to the university; 2)
disclosure in publications and to subjects in clinical trials; 3)
research monitoring; 4) modification of the research plan; 5)
disqualification of investigator; 6) designation of a co-
investigator; 7) sale or transfer of relevant financial interest to
a blind trust; and/or 8) severance of relationship with the
sponsor.
Disclosure of conflict of interest to human subjects is also
an issue in clinical trials. Informed consent is mandated by
human subject protection regulations of the Department of
Health and Human Services (DHHS). These human subject
protection procedures are managed and administered by In-
stitutional Review Boards (IRBs), the composition and oper-
ation of which are delineated in federal guidelines. Each
institution files an assurance with the DHHS’s Office for
Protection from Research Risks, stipulating that the local IRB
follows procedures substantially similar to those outlined in the
federal regulations. Recent, well-publicized examples of scien-
tific misconduct as well as heightened public concern regarding
issues such as radiation exposure have increased the level of
IRB scrutiny. Consequently, cardiologists and other investiga-
tors can expect steadily increasing regulatory requirements for
human research. The information required for informed con-
sent includes the risk (including the risk of loss of confidenti-
ality regarding a real or suspected medical condition), poten-
tial benefits, potential new knowledge, alternative diagnostic or
therapeutic choices, costs, and the potential conflict between
financial gain for the investigator and scientific judgment. As in
other situations involving the disclosure of potentially complex
and arcane information to an individual not conversant with
the field of endeavor, the burden of explanation falls on the
investigator.
Payer Confusion Regarding Reimbursement for
Experimental Procedures
An additional major issue is the off-label use of approved
devices for nonapproved indications. Current narrow clinical
indications and highly specific product labeling have fostered
off-label use which has potential legal and regulatory implica-
tions. Operators now fear punitive action when they use a
device that is appropriate for their patients if the labeling does
not recognize that indication.
The problem extends to Medicare/Medicaid reimburse-
ment. Physicians and hospitals are reimbursed for medical
services rendered to beneficiaries provided that the service is
approved by the Health Care Financing Administration
(HCFA). Pursuant to Section 1862 (a)(1)(A) of the Social
Security Act, the HCFA is permitted to reimburse for medical
services and procedures which are deemed reasonable and
necessary for the diagnosis or treatment of an illness or injury.
The Medicare program has historically interpreted the statu-
tory terms reasonable and necessary to mean that a service or
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medical device must be safe and effective, medically necessary
and appropriate, and not experimental in order to qualify for
reimbursement. If the procedure or device has not been
approved, hospitals and physicians may not seek reimburse-
ment from Medicare. Recently, however, even FDA approval
has not been taken as a sufficient criterion for Medicare
reimbursement. Historically, Medicare provided reimburse-
ment for nonapproved FDA medical products on a case-by-
case basis through recommendations made by Peer Review
Organizations and various Medicare contractors.
The confusion over reimbursement criteria has been high-
lighted by the Office of the Inspector General’s (OIG) inves-
tigation, begun in response to charges brought forth by a
whistleblower in 1994. The OIG is investigating allegations
that hospitals and physicians were wrongfully billing Medicare
for nonapproved medical products and has issued subpoenas
to 135 hospitals nationwide regarding the implantation of
investigational devices in clinical trials under an IDE. Al-
though the HCFA knew that hospitals were receiving payment
for services found to be necessary and reasonable by Physician
Review, Medicare based its interpretation of what is experi-
mental solely on FDA action, excluding coverage of proce-
dures involving non-FDA–approved devices as not reasonable
and necessary.
Following the announcement of the OIG investigation, the
HCFA sought to clarify existing Medicare policy for physician
and hospital reimbursement. Under a new rule adopted by the
HCFA on November 1, 1995, the FDA created a new catego-
rization process to assist the HCFA in determining which
medical services qualify for reimbursement under Medicare
(9). Each device with an FDA-approved IDE is assigned to one
of two categories: experimental/investigational (Category A)
devices, or nonexperimental/noninvestigational (Category B)
devices (10).
At present the OIG has agreed to limit its inquiry to
nonapproved medical devices and dropped its plan to focus on
nonapproved off-label uses. Additionally, the Federal District
Court in Los Angeles has granted a summary judgment in
favor of 25 hospitals that were under investigation by the OIG
for billing Medicare for services which included a device not
yet approved for marketing by the FDA. The Court ruled that
the HCFA had not issued a clear policy statement governing
payment for such medical products, therefore invalidating the
OIG’s investigation concerning non-FDA–approved devices.
The government is currently appealing this decision.
The Divergent Perspectives of Technology
Approval and Assessment
The Perspective of the FDA
The FDA perceives its mission as the promotion of the
public health through timely approval of medical devices which
are safe, effective and appropriately labeled. Therefore, it must
base its regulatory decisions on valid scientific evidence from
properly designed clinical trials that establish the safety and
effectiveness of the new device. As a regulatory body with a
great deal of oversight from politicians, interest groups and
journalists, the FDA is in the unenviable position of being
criticized for making the smallest mistake, and never rewarded
for taking risk. Its procedures are designed to withstand
political criticism and tend to be long and detailed. From the
FDA perspective, not every sponsor develops their device in a
logical fashion. Many studies, conducted without prior FDA
input, seem to lack scientific merit. Prospectively defined,
objective endpoints that establish device effectiveness are often
lacking. To better communicate requirements, the FDA urges
early interaction with the sponsor and principal investigator.
Such interaction should precede the IDE submission.
The FDA will support integrating premarketing and post-
marketing activities, and earlier PMA, provided that the
overall clinical plan is rational, safe, and has the appropriate
balance between earlier public access and more detailed
clinical data. In certain circumstances, PMA supplements with
adequate preclinical data and appropriate postmarketing stud-
ies could be approved without premarketing clinical studies.
The Perspective of the Practicing Cardiologist
The perspective of the practicing cardiologist is patient
advocacy. The physician aims to optimize patient outcome with
the minimum delay. When the pace of technologic change is
rapid, cardiologists believe that both patients and society are
not well served by the current approval and assessment system.
The physician’s view is that iterative changes of similar devices
should have a facilitated approval process. In addition, cardi-
ologists argue that it is wrong to deny Medicare beneficiaries
access to the latest medical advances simply because the newer
devices are waiting approval by the FDA. Finally they fear that
if hospitals continue to limit clinical trials in response to the
threat of fraud litigation, some devices may never reach the
general market, forcing overseas development.
The Perspective of Industry
Although industry perspectives are varied, in recent years
there is a consensus that present methods for assessing and
approving technology are excessively costly and time consum-
ing, particularly in light of the lack of any evidence or
cost/benefit analysis that public safety is being enhanced by the
increasingly stringent requirements of the FDA approval pro-
cess (11).
Industry also sees the issues of technology assessment as
inextricably tied to the larger issue of health system reform,
making the trade-offs between health care financing, delivery
and quality more and more difficult (12). Manufacturers also
feel that the managed care community has made it increasingly
difficult to introduce new technologies or deviate from stan-
dards of practice. Industry sees the FDA and the academic
medical establishment as unlikely supporters of managed care
by insisting on rigorous scientific proof that a new device is
more beneficial and cost-effective than the one it is intended to
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replace. In industry’s view, the benefits of greater scientific
rigor and accuracy are more than offset by the liabilities of
increased cost and time to develop new technology, and by the
limited clinical relevance of scientific results that are obsolete
by the time they are published.
The Perspective of Payers
Payers want to know which tests and treatments should be
reimbursed and at what level. Historically, acceptance of a new
technology for reimbursement was based primarily on FDA
approval. Payers see inherent contraindications when devices
labeled as experimental are concurrently identified and utilized
by the medical community as the standard of care in off-label
applications.
These different views of technology assessment serve to
illustrate the difference between safety (the potential to cause
harm), efficacy (ability to produce the intended result), effec-
tiveness (utilization in actual practice) and cost-effectiveness.
FDA regulatory approval is based on the first two factors;
physician and patient acceptance is influenced by the third and
payer reimbursement by the fourth. The key to developing an
effective method for technology assessment, therefore, is the
phasing of information acquisition and analysis, and of ap-
proval and assessment. Device approval prior to marketing,
which typically analyzes efficacy, must be linked to postmarket
assessment of safety and effectiveness. At present, however,
device approval is often the last rigorous step in technology
assessment.
Technology Assessment:
Meeting the Nation’s Needs
The flaws in the current system of technology approval and
assessment are summarized in Table 2. The time required to
bring effective new technology to patient care is far too long.
The assessment of safety is conducted in highly selected, low
risk subgroups that do not represent the patients subsequently
treated in practice. The resulting off-label use of devices has
created chaos among payers and providers. The postmarket
analysis of device performance is inadequate. Research and
development in the United States is transferred overseas.
Finally, although not calculable, the cost of all these problems
is undoubtedly in the billions of dollars. Solutions to the
problems could lie in legislation or in restructuring the system.
In this section, the Task Force considers these two alternatives.
Proposed Congressional Reform
Throughout the 104th Congress, FDA reform was a pri-
mary focus of the congressional leadership. Senator Nancy
Landon Kassebaum (R-KA) introduced the FDA Performance
and Accountability Act of 1995 (S.1477) which was approved
on March 28 by the Senate Labor and Human Resources
Committee by a vote of 12 to 4 (13). The bill would amend the
FDA Act and the Public Health Service Act to improve the
regulation of food, drugs, medical devices, and biological
products. This bill would require the FDA to complete at least
95 percent of new product approval applications within set
statutory deadlines; allow outside review boards to conduct
product review under certain circumstances; expand access to
experimental drugs and medical devices; reduce the quantity of
data the FDA would require from industry during the approval
process; and improve communication with regulated indus-
tries. An original provision of the bill would have allowed
manufacturers to distribute information on off-label uses for
medical drugs.
On the House side, the most notable bills were those
proposed by the Chair of the legislative task force of Com-
merce Committee Republicans, Congressman James Green-
wood (R-PA) (HR 3199, HR 3200, and HR 3201). These bills
address the areas of medical devices, drugs and biologics, and
foods. The bills would allow manufacturers to submit applica-
tions directly to a third-party review board if the FDA failed to
meet the statutory deadlines, with private industry absorbing
the cost of review. Although these FDA reform proposals
received significant bipartisan support, all measures were
unsuccessful in gaining approval during the 104th Congress.
Republican members of Congress and administration officials
have promised to reconsider FDA reform proposals in 1997.
On October 8, 1996, the FDA issued new guidelines on the
dissemination of information by companies to health care
professionals regarding off-label uses of their products. The
guidance will allow industry to disseminate information on
off-label uses through peer-reviewed journals and textbooks;
however, industry representatives will not be permitted to
promote information in the disseminated text that is not
consistent with the approved labeling for a product. The
information must clearly state that some data are for off-label
use. The ACC commented favorably on this regulation when it
was proposed but suggested that the FDA could go further in
fostering the dissemination of new clinical information.
The ACC strongly advocates reform to decrease the com-
plexity and length of approval time for pharmaceuticals and
devices. The ACC recognizes the need for physicians and other
health care professionals to have access to accurate and
unbiased information about pharmaceuticals and medical de-
vices. The ACC supports the exchange of public scientific
information on off-label uses of pharmaceuticals and devices,
while recognizing the publication of such peer-reviewed infor-
mation must be handled with the utmost regard for patient
safety. Many off-label indications of previously approved phar-
maceuticals and devices are widely recognized as accepted by
physicians but are not part of FDA-approved labeling. The
ACC encourages the development of alternative mechanisms,
including lengthy clinical experience, which would allow peti-
tions for inclusion of a supplemental indication on FDA-
approved labeling. The College supports the ability of the FDA
to contract with qualified, non-FDA organizations for review
of new pharmaceuticals and devices to facilitate the review
process, if public safety is not compromised. The ACC is
supportive of voluntary pilot projects to test the feasibility of
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third-party reviews of low to moderate risk devices. Finally, the
ACC is committed to providing unbiased professional guid-
ance to both industry and the FDA.
Although the ACC believes that continued improvements
are desirable, it does not support reforms that would mandate
strict time frames for FDA approval unless additional funding
is provided. Furthermore the ACC does not support complete
transfer of the approval process from the FDA to private
contractors. Finally, the ACC does not support changes that
would require increased FDA responsibility unless the agency
receives a commensurate increase in resources.
Recommendations of the Task Force on
Technology Assessment
The Bethesda Conference Task Force on Technology As-
sessment believes that major improvement in technology ap-
proval and assessment, meeting the needs of all users, can be
readily accomplished within the current structure, which has
many merits as well as the previously cataloged deficiencies.
The Task Force proposes establishment of a new category of
conditional approval for new technology. The proposed new
category of provisional FDA approval would require accept-
able data to demonstrate preliminary safety and efficacy,
including bench testing, preclinical data, and pilot clinical
studies. Provisional approval would give limited labeling (i.e., a
narrow indication), but there would be prestipulated condi-
tions of final approval, including
1. Completion of a comprehensive clinical trial in a speci-
fied time frame. The trial would include a wide spectrum of
patient categories and indications, reflecting anticipated use in
clinical practice.
2. Marketing of the device by the manufacturer only for the
limited label.
3. Full acknowledgment that the new device approval
could be rescinded if the data generated do not support its
use or if the data were not available in the designated time
period.
The advantages of this new structure are that it will:
1. Provide far better insight on true efficacy and safety in a
broad population of patients.
2. Limit off-label use, by expanding the patient subsets in
which new technology is tested.
3. Provide early access to promising new technology and
extend safety and efficacy analysis to postmarket approval.
4. Allow more rapid introduction of new devices into
clinical practice.
5. Improve global competitiveness in the United States for
new technology assessment.
6. Achieve this within the confines of preexisting legisla-
tion.
To facilitate this process, the ACC would agree to work
with the FDA in technology assessment in the following ways:
1. Participate in defining criteria for provisional device
approval.
2. Advise FDA on Advisory Panel membership, including
ad hoc membership.
3. Advise the FDA and the Advisory Panel on design of
clinical trials.
4. Periodically draft Position Statements on the need for
trials.
5. Conduct postmarket technology assessment using FDA-
mandated clinical trial results and other data published in
scientific journals.
The Task Force proposes, and the Bethesda Conference
unanimously supported, this plan as an optional alternative to
the conventional approval pathway. While the intent of provi-
sional FDA approval is directed toward enabling devices to
reach the U.S. market in a more expeditious manner, the Task
Force also recognized that it is uncertain whether this proposal
requires new legislation or whether there is sufficient latitude
in the current FDA IDE regulations to allow immediate
implementation. Consequently, the Task Force also recom-
mends continued dialogue between the FDA, the ACC and the
organizations representing patients, physicians and the busi-
ness community to determine the legality and practicality of its
proposal, and to explore all possible avenues for improvement
in the system for approval and assessment of medical devices in
the United States.*
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